Entries |
Document | Title | Date |
20080199478 | Combinations of Immunosupressive Agents for the Treatment or Prevention of Graft Rejections - A pharmaceutical composition useful in the treatment or prevention of transgenic xenograft rejection comprising immunosuppressant compounds selected from the group consisting of an IL-2 transcription inhibitor and immunosuppressant compounds that immunosuppress for B-cell-mediated or antibody-mediated rejection of xenografts, and pharmaceutically acceptable diluents or carriers, and a method of preventing hyperacute rejection, reducing early graft damage, improving early xenograft function and promoting long term survival of said transgenic xenografts comprising the steps of i) contacting the body fluid removed from a human recipient with a xenoantigenic material which is bound to a biocompatible solid support, ii) reintroducing the treated body fluid into the recipient, and iii) treating the recipient with said pharmaceutical composition. | 08-21-2008 |
20080206253 | Method For Preventing or Treating Pain in a Mammal - Methods are provided for preventing or treating pain in a mammal comprising administering an inhibitor of p38β MAP kinase in a therapeutically effective amount to the mammal in need thereof. | 08-28-2008 |
20080213273 | Single dose use of CD20-specific binding molecules - The present invention provides materials and methods for treatment of diseases involving aberrant B-cell activity using a single dose of CD20-specific binding molecule. | 09-04-2008 |
20080213274 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF FIBROTIC, INFLAMMATORY, AND NEOVASCULARIZATION CONDITIONS OF THE EYE - The present invention relates to compositions and methods for prevention and treatment of ocular diseases and conditions characterized by aberrant fibrogenesis or scarring, inflammation and/or aberrant neovascularization or angiogenesis. The compositions and methods of the invention utilize immune-derived moieties that are specifically reactive against bioactive lipids and which are capable of decreasing the effective concentration of said bioactive lipid. In some embodiments, the immune-derived moiety is a monoclonal antibody that is reactive against sphingosine-1-phosphate (S1P) or lysophosphatidic acid (LPA). | 09-04-2008 |
20080213275 | USE OF MTKI 1 FOR TREATING OR PREVENTING BONE CANCER - The present invention is concerned with the finding that the macrocyclic quinazoline derivative 4,6-ethanediylidenepyrimido[4,5-b][6,1,12]benzoxadiazacyclo-pentadecine, 17-bromo-8,9,10,11,12,13,14,19-octahydro-20-methoxy-13-methyl-, described as compound 22 in PCT publication WO2004/105765, is useful in the manufacture of a medicament for the treatment or prevention of bone cancers and methods for killing bone cancer cells, including osteosarcomas, chondrosarcomas, myeloma bone disease and osteolytic bone metastases from other primary sites. It accordingly provides methods for treating, preventing, delaying or mitigating bone cancer, or for preventing and treating of bone loss associated with cancer metastases. | 09-04-2008 |
20080213276 | Modulation of neural stem cells and neural progenitor cells - The invention relates generally to methods of influencing central nervous system cells to produce progeny useful in the treatment of CNS disorders. More specifically, the invention includes methods of exposing a patient suffering from such a disorder to a reagent that modulates the proliferation, migration, differentiation and survival of central nervous system cells via S1P or LPA signaling. These methods are useful for reducing at least one symptom of the disorder. | 09-04-2008 |
20080213277 | HEPCIDIN, HEPCIDIN ANTAGONISTS AND METHODS OF USE - The invention relates to purified, correctly folded hepcidin, antibodies that bind hepcidin, and methods of making and using such materials. Also provide are methods of treated hepcidin-related disorders. | 09-04-2008 |
20080219994 | MODIFIED BOUGANIN PROTEINS, CYTOTOXINS AND METHODS AND USES THEREOF - The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer. | 09-11-2008 |
20080219995 | IL-32 MONOCLONAL ANTIBODIES AND USES THEREOF - The present invention provides monoclonal antibodies specific for interleukin-32 (IL-32, previously referred to as “natural killer cell transcript 4” or “NK4”) and hybridomas secreting monoclonal antibodies specific for IL-32. Also provided are diagnostic methods and kits (e.g., ELISA, Western blot, etc.) which utilize monoclonal antibodies specific for IL-32. | 09-11-2008 |
20080226648 | Methods for Treating Stress and Affecting Biological Immune Systems - The subject invention provides materials and methods for treating stress and/or augmenting immune response. More specifically, the present invention provides methods for the treatment and/or prevention of stress-related physiological responses; the alleviation of stress-related symptoms; as well as the prevention or delay in development of stress-related complications. The present invention further provides biologically-active compounds that can cause the thymus and spleen to increase in size and. cause an increase in villi length and goblet cell production in mucosae. Specifically exemplified herein is the use of a cysteamine compound to modulate immune responsiveness and/or treat stress. | 09-18-2008 |
20080226649 | CPG-like nucleic acids and methods of use thereof - Immunostimulatory compositions described as CpG-like nucleic acids are provided, including nucleic acids having immunostimulatory characteristics of CpG nucleic acid, despite certain substitutions of C, G, or C and G of the CpG dinucleotide. The substitutions can include, among others, exchange of methylated C for C, inosine for G, and ZpY for CpG, where Z is cytosine or dSpacer and Y is inosine, 2-aminopurine, nebularine, or dSpacer. Also provided are methods for inducing an immune response in a subject using the CpG-like nucleic acids. The methods are useful in the treatment of a subject that has or is at risk of developing an infectious disease, allergy, asthma, cancer, anemia, thrombocytopenia, or neutropenia. | 09-18-2008 |
20080226650 | COTININE NEUTRALIZING ANTIBODY - The present application discloses monoclonal antibody against cotinine and nicotine. | 09-18-2008 |
20080226651 | COMPOUNDS CAPABLE OF INHIBITING HIV-1 INFECTION - This invention provides an antibody capable of specifically inhibiting the fusion of an HIV- | 09-18-2008 |
20080241157 | Nerve cell growth modulators (amphibodies) - The present invention relates to a nerve cell growth modulator denoted an amphibody. The amphibody according to the invention is comprised of at least two components, wherein a first component is capable of binding to a target and suppressing, or essentially neutralising, a nerve cell growth inhibitory effect thereof; and a second component is capable of stimulating nerve cell growth and/or regeneration. In the most preferred embodiment, the present amphibody is a neuromodulator comprised of the above disclosed two components connected by a linker element. Amphibodies according to the invention are a useful means of molecular disguise of a non-permissive environment into a permissive, and outgrowth promotive and favorable one. The present invention also relates to genetic and chemical methods of preparation of an amphibody according to the invention as well as to various advantageous uses thereof. | 10-02-2008 |
20080241158 | Human taste-specific receptor TIR3 - The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and encode GCREC. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC. | 10-02-2008 |
20080241159 | METHODS AND COMPOSITIONS FOR SELECTIVE MODULATION OF VASCULARIZATION - The invention provides methods and compositions for modulating vascularization and angiogenesis, including selective modulation of stages of multi-step vascularization and angiogenesis. | 10-02-2008 |
20080254036 | COMBINATION ANTICOAGULANT THERAPY WITH A COMPOUND THAT ACTS AS A FACTOR XA INHIBITOR - The present invention is directed to methods of using combination therapies containing [2-({4-[(dimethylamino)iminomethyl]phenyl}carbonylamino)-5-methoxyphenyl]-N-(5-chloro(2-pyridyl))carboxamide for the treatment of thrombotic disease(s) and pharmaceutical compositions thereof. | 10-16-2008 |
20080260748 | Methods for Damaging Cells Using Effector Function of Anti-Dsc2 Antibody - The present invention is based on the discovery that the cytoxicity of anti-desmocollin 2 (DSC2) antibodies can be used for treating various cancers including lung, colon, pancreatic, prostate, breast, gastric or liver cancers. Specifically, the present invention provides antibodies against DSC2 that have effector function. Furthermore, the present invention provides methods and pharmaceutical compositions that comprise anti-DSC2 antibody as an active ingredient for damaging DSC2-expressing cells via the effector function of the antibody. | 10-23-2008 |
20080260749 | Novel Tetrahydropyridothiophenes - Compounds of a certain formula (I) | 10-23-2008 |
20080267969 | Treatment of Pulmonary Hypertension Using an Agent That Inhibits a Tissue Factor Pathway - An improved non-human animal model of severe pulmonary arterial hypertension (PAH) and its use for testing of therapeutic agents that can treat symptoms of PAH are disclosed. In addition, the present application relates to the identification of several classes of therapeutic agents that, alone or in combination, can be used to treat or prevent PAH or at least reduce the severity of symptoms associated therewith. Both gene therapy and non-gene therapy approaches are described. | 10-30-2008 |
20080267970 | Sulfonamide Derivatives For The Treatment of Diseases - The invention relates to compounds of formula (1) | 10-30-2008 |
20080274116 | Lipids, Lipid Complexes and Use Thereof - The present invention is related to a compound according to formula (I), wherein R | 11-06-2008 |
20080274117 | Validation of Tssk Family Members and Tsks as Male Contraceptive Targets - The present invention relates to a family of testis specific kinases (the TSSK family) and a substrate (TSKS) of TSSK, nucleic acid sequences encoding those kinases and substrate, and antibodies and antagonists against the kinases and substrate, methods of regulating these proteins, and their use as contraceptive targets. | 11-06-2008 |
20080279856 | Inhibition of Bradykinin Release - The invention is related to a method for treating or preventing a disorder resulting from the release of bradykinin in said mammal, particularly a mammal which produces a HBP which binds to a HBP antagonist, e.g. a monoclonal antibody that binds to at least one epitope of human HBP, comprising administering to said mammal a HBP antagonist in an amount effective to decrease the release of bradykinin in a mammal. Furthermore, the invention is directed to methods and kits for determining if a mammal produces HBP that binds to a HBP antagonist, e.g., a monoclonal antibody that binds to at least one epitope of human HBP and a method for detecting an antagonist of HBP. | 11-13-2008 |
20080279857 | Therapeutic Agent - The present invention relates to agents which modulate the effect of a RAMP (Receptor Activity Modifying Protein) protein on a Calcitonin Receptor Like Receptor (CRLR). Also included in the present invention are methods and uses of such agents and assays for identifying such agents. The agents of the present disclosure may be used in the treatment of, for example, cancer, obesity and other disorders. | 11-13-2008 |
20080286279 | Treatment of Severe Community-Acquired Pneumonia by Administration of Tissue Factor Pathway Inhibitor (Tfpi) - Methods for prophylactically or therapeutically treating severe pneumonia involve administration of tissue factor pathway inhibitor (TFPI) or a TFPI analog to patients suffering from or at risk of developing this condition. The methods involve the use of continuous intravenous infusion of TFPI or a TFPI analog, preferably at low doses to avoid adverse side effects. | 11-20-2008 |
20080286280 | Stable Lyophilized Pharmaceutical Preparations of Monoclonal or polyclonal antibodies - The invention concerns lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies which contain a sugar or an amino sugar, an amino acid and a surfactant as stabilizers. In addition the invention concerns a process for the production of this stable lyophilisate as well as the use of a sugar or amino sugar, an amino acid and a surfactant as stabilizers for therapeutic or diagnostic agents containing antibodies. | 11-20-2008 |
20080292637 | Therapeutic Uses of A3 Adenosine Receptor Antibodies - The present invention concerns the use of an anti-A3 adenosine receptor (A3AR) immunoglobulin-based molecule for the preparation of a pharmaceutical composition for the treatment of a pathological condition associated with a high level of expression of A3 adenosine receptor. Further provided by the invention is a method of treating a pathological condition associated with a high level of expression of A3 adenosine receptor in a subject, the method comprising administering to said subject an amount of the anti-A3AR immunoglobulin-based molecule, the amount being effective to treat or prevent said pathological condition. Finally, the present invention provides a pharmaceutical composition for the treatment of a pathological condition associated with a high level of expression of A3AR comprising a physiologically acceptable carrier and the anti A3AR immunoglobulin-based molecule. | 11-27-2008 |
20080292638 | Tgf-Beta Binding Antibodies - The present invention provides very high affinity antibodies, or antigen-binding fragments thereof, that neutralize mature human TGF-β1, TGF-β2, and TGF-β3. The antibodies of the invention are useful for treating cell proliferative disorders in a mammal. | 11-27-2008 |
20080299128 | Effect of Bst2 on inflammation - The application disclose a method of preventing immune cells from binding to other cells, which includes contacting the immune cells and the other cells with a composition comprising Bst2 antagonist. | 12-04-2008 |
20080305113 | Pharmaceutical Composition for Preventing or Treating Chronic Graft-Versus-Disease Comprising Anti-CD137 Monoclonal Antibody - Provided is a pharmaceutical composition for preventing and treating chronic graft-versus-host disease (cGVHD) containing an anti-CD137 monoclonal antibody. | 12-11-2008 |
20090004197 | Dek Protein Compositions and Methods of Using the Same - The present invention relates to DEK protein compositions (e.g., antibodies, small molecule inhibitors, siRNAs) and methods of using the same. In particular, the present invention provides compositions and methods for treating autoimmune disease (e.g., juvenile rheumatoid arthritis, lupus, etc.) and for inhibiting inflammation (e.g., associated with autoimmune disease) and cellular chemotaxis (e.g., of neutrophils, NK cells and T cells). The present invention further provides a diagnostic marker (e.g., DEK antigen) for autoimmune disease. | 01-01-2009 |
20090010937 | Membrane Attack Complexes Associated with Circulating Immune Complexes - The invention relates to demonstrate the presence of non covalently linked complement proteins with CIC. Invention demonstrate the presence of C5 and MAC on CIC. The invention provides methods to measure M complement proteins C1q, C3, C4, C5 bound to CIC as markers of disease activity and pathogenicity for complement and CIC mediated diseases. The invention also relates to modifications and blocking of formation of MAC on the CIC by developing a useful reagent that can be monoclonal antibody, active molecule, mimotope or peptide molecule. The invention describes usefulness to reduce the non-covalent complement components, formation of MAC and association of C5 to CIC for therapeutic application in pathological disease with involvement of CIC and complement. | 01-08-2009 |
20090010938 | SHORT IMMUNOMODULATORY OLIGONUCLEOTIDES - The invention relates to modulation of the immune system. More particularly, the invention relates to modulating the immune system through the use of oligonucleotide-derived compounds. The invention provides immunostimulatory agents that are less expensive to make than existing immunostimulatory oligonucleotides. The immunostimulatory agents according to the invention can, in preferred embodiments, cause immune stimulation across species lines. | 01-08-2009 |
20090017036 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS - The present invention relates to novel pharmaceutical compositions comprising at least one EGFR kinase inhibitor and at least one additional active compound selected from beta-2 mimetics, steroids, PDE-IV inhibitors, p38 MAP kinase inhibitors, NK | 01-15-2009 |
20090022726 | METHOD OF USING IL6 ANTAGONISTS WITH PROTEASOME INHIBITORS - The invention is directed to a method of treating a cancerous disorder or condition, or an IL- | 01-22-2009 |
20090022727 | INJECTABLE, NONAQUEOUS SUSPENSION WITH HIGH CONCENTRATION OF THERAPEUTIC AGENT - An injectable, nonaqueous suspension including at least one therapeutic agent suspended in a single component vehicle. The single component vehicle is a single amphiphilic material, such as a polyethoxylated castor oil or derivative thereof, a polyoxyethylene alkyl ether, a polyoxyethylene sorbitan fatty acid ester, a polyoxyethylene stearate, a block copolymer of polyethylene oxide-polypropylene oxide-polyethylene oxide, a block copolymer of polypropylene oxide-polyethylene oxide-polypropylene oxide, a tetra-functional block copolymer of polyethylene oxide-polypropylene oxide, or a tetra-functional block copolymer of polypropylene oxide-polyethylene oxide. A dosage kit that includes the injectable, nonaqueous suspension and a method of administering the injectable, nonaqueous suspension are also disclosed. | 01-22-2009 |
20090022728 | METHODS OF TREATING OPHTHALMIC DISEASES - Methods of using inhibitors (including monoclonal antibodies) directed against amyloid-beta peptide for the treatment of ophthalmic diseases such as age-related macular degeneration are described. | 01-22-2009 |
20090028866 | USE OF CCR9, CCL25/TECK, AND NITEGRIN alpha4 IN DIAGNOSIS AND TREATMENT OF MELANOMA METASTASIS IN THE SMALL INTESTINE - The invention relates to methods for determining whether a melanoma will metastasize or has metastasized to the small intestine in a subject by detecting or quantifying the expression of the CCR9, CCL25/TECK, or integrin α4 gene. Also disclosed are methods for treating subjects so identified. | 01-29-2009 |
20090028867 | Antagonists Specific For Denatured Collagen And Methods Of Using Same - The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen but not to native triple helical forms of the collagen. Antagonists of the invention can target, for example, denatured collagens type-I, type-II, type-III, type-IV, type-V and combinations thereof. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis in normal or diseased tissues both in vivo and ex vivo. Antagonists include monoclonal antibodies referred to as HU177, HUIV26, and XL313. | 01-29-2009 |
20090028868 | Anti-cancer pharmaceutical compositions and methods for treating patients with cancer - Method of treating persons having carcinoma, sarcoma or hematopoietic cancer by administering (i) a compound of the formula (I) | 01-29-2009 |
20090035313 | Compounds - This invention relates to nicotinamide derivatives of general formula (I): | 02-05-2009 |
20090035314 | Method and pharmaceutical composition for preventing or treating diseases associated with inflammation - The present invention relates to a method and pharmaceutical composition for preventing or treating inflammatory diseases. More particularly, the present invention relates to a method for inhibiting lymphocyte adhesion to an endothelial cell, or a method for treating an inflammatory disease, which comprises administering to a subject in need thereof an inhibitor against lymphocyte adhesion to a FEX-2 polypeptide. A pharmaceutical composition comprising the inhibitor against lymphocyte adhesion to a FEX-2 polypeptide, and the use of the inhibitor against lymphocyte adhesion to a FEX-2 polypeptide are also disclosed. Further, a method for screening a medicament for inhibiting lymphocyte adhesion to a FEX-2 polypeptide or a medicament for treating an inflammatory disease, which comprises a step of selecting an inhibitor against lymphocyte adhesion to a FEX-2 polypeptide, is disclosed. | 02-05-2009 |
20090041775 | Use of CD25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract - Use of a CD25 binding molecule which comprises at least one antigen binding site comprising at least one domain which comprises in sequence, the hypervariable regions CDR1, CDR2 and CDR3; said CDR1 having the amino acid sequence Arg-Tyr-Trp-Met-His, said CDR2 having the amino acid sequence Ala-Ile-Tyr-Pro-Gly-Asn-Ser-Asp-Thr-Ser-Tyr-Asn-Gln-Lys-Phe-Glu-Gly, and said CDR3 having the amino acid sequence Asp-Tyr-Gly-Tyr-Tyr-Phe-Asp-Phe, in the treatment of inflammatory disease of the gastro-intestinal tract. | 02-12-2009 |
20090041776 | Production of cancer-specific antibodies in plants - The invention as described herein provides compositions and methods for cancer immunotherapy and cancer detection. In particular, the invention discloses plant-derived human monoclonal antibodies that bind human carcinoma antigens in cancer cell lines. | 02-12-2009 |
20090047288 | Glucan compositions and methods of enhancing CR3 dependent neutrophil-mediated cytotoxicity - A 25 kD β-glucan composition is described herein that effects the CR3-dependent priming of neutrophils and can promote neutrophil killing of iC3b-opsonized targets. Also described herein are methods of enhancing neutrophil cytotoxicity locally at the site of the tumor. | 02-19-2009 |
20090047289 | Osteopontin Specific Antibodies and Methods of Use Thereof - Monoclonal antibodies immunospecific for osteopontin are disclosed. Also provided are therapeutic methods of use thereof for modulating osteopontin levels for the treatment of autoimmune disorders. | 02-19-2009 |
20090053233 | Cytotoxic Antibody Directed Against Type B Lymphoid Hematopoietic Proliferations - The present invention relates to a monoclonal antibody directed against the CD20 antigen, wherein the variable region of each of the light chains thereof is encoded by a sequence which shares at least 70% identity with murine nucleic acid sequence SEQ ID No. 5, the variable region of each of the heavy chains thereof is encoded by a sequence which shares at least 70% identity with murine nucleic acid sequence SEQ ID No. 7, and the constant regions of light and heavy chains thereof are constant regions from a non-murine species, as well as for activation of FcγRIIIA receptors in immune effector cells, and for the manufacture of a drug especially for the treatment of leukaemia or lymphoma. | 02-26-2009 |
20090060919 | BINDING MEMBERS FOR IgE MOLECULES - This invention relates to binding members, especially antibody molecules, for IgE. The binding members are useful for, inter alia, treatment of disorders mediated by IgE including allergies and asthma. | 03-05-2009 |
20090068189 | Monoclonal Antibody to Human TGF-Beta Induced Gene-H3 and Use Thereof - The present invention relates to a monoclonal antibody to human βig-h3 and the use thereof. More particularly, it relates to a monoclonal antibody to the human βig-h3 protein, wherein the epitope of the monoclonal antibody is the H1 region of the fourth fas-1 domain of the human βig-h3 protein. The monoclonal antibody can specifically recognize the human βig-h3 protein in tissue, and so will be useful in diagnosing a disease associated with the increase or decrease of the βig-h3 protein. In addition, the monoclonal antibody has the effect of inhibiting the cell adhesion activity of the βig-h3 protein. | 03-12-2009 |
20090068190 | ANTI-PROLIFERATIVE COMBINATIONS - Combinations of a polyunsaturated fatty acid and diindolylmethane and pharmaceutical composition containing such combinations. Further provided are combinations including a polyunsaturated fatty acid, diindolylmethane, and folic acid. Also provided are combinations including diindolylmethane and folic acid. Also provided is a method for increasing the number of normal cells and decreasing the number of aberrant cells in a subject having the steps of administering to the subject a combination comprising a polyunsaturated fatty acid and diindolylmethane. | 03-12-2009 |
20090074784 | Treatment of chronic viral diseases with antibodies to costimulating polypeptide of T cells - A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against the 8F4 molecule and hybridoma cells which produce the monoclonal antibodies, the use as medicaments of substances which inhibit the biological activity of the 8F4 polypeptide, in particular monoclonal antibodies, natural or synthetic ligands, agonists or antagonists, in particular for preventing or treating diseases which involve the immune system, the use of the 8F4 molecule or cells containing the 8F4 molecule as medicaments, in particular for preventing or treating diseases which involve the immune system, and the use of substances which specifically recognize the 8F4 polypeptide, in particular monoclonal antibodies, natural or synthetic ligands, agonists or antagonists, for diagnosing diseases which involve the immune system. | 03-19-2009 |
20090074785 | Compositions and methods for treatment of colorectal cancer - We have identified a new variant of ileal bile acid binding protein (IBABP), designated IBABP-L, which is a biomarker for colorectal cancer. The transcript for IBABP-L arises from an alternative start site and includes three exons that are absent in IBABP. IBABP-L also shares part of a fourth exon with IBABP. The protein encoded by IBABP-L contains a deduced 49 residue N-terminal sequence that is not found in the IBABP protein. The present invention provides, for example, compositions and methods for diagnosing and treating colorectal cancer. | 03-19-2009 |
20090074786 | FORMULATIONS FOR TREATING OCULAR DISEASES AND CONDITIONS - Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; non-dispersed mass-forming liquid formulations which form a gel or gel-like substance in an aqueous medium; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration, or placement proximate to a site of a disease or condition to be treated in a subject. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration, or wet age-related macular degeneration in a subject. The liquid formulations may comprise rapamycin or other therapeutic agents. | 03-19-2009 |
20090087440 | Methods for Treating Cancer - Dendritic cells (DC) play a critical role in antigen-specific immune responses. Materials and Methods are provided for treating disease states, including cancer, by activating dendritic cells from the host which are rendered hypo-responsive to activation stimuli by the disease. In particular, methods are provided for treating cancer in a mammal comprising administering to said mammal an effective amount of a tumor-derived DC inhibitory factor antagonist in combination with an effective amount of a Toll-like receptor (TLR) agonist. | 04-02-2009 |
20090087441 | Wortmannin Analogs and Methods of Using Same in Combination with Chemotherapeutic Agents - Novel wortmannin analogs and their use in inhibiting PI-3-kinase activity in mammals and the treatment or prevention of cancer and tumor formation in a subject are described herein. Preferably, the wortmannin analogs may be administered with other chemotherapeutic agents in the treatment of cancer. | 04-02-2009 |
20090092619 | METHODS AND COMPOSITIONS FOR MALARIA PROPHYLAXIS - A composition for preventing malaria infection including a steric inhibitor of circumsporozoite protein cleavage. A pharmaceutical composition for preventing malaria infection including a steric inhibitor and a pharmaceutical carrier. A method of malaria infection prophylaxis including the step of administering an effective amount of the composition of the present invention. A method of malaria prophylaxis by sterically inhibiting circumsporozoite protein processing or by directly inhibiting a protease of a sporozoite from binding to its target. Methods of preventing sporozoite cell invasion or preventing circumsporozoite processing through steric or direct inhibition. | 04-09-2009 |
20090098133 | Tetrahydropyridothiophenes as Antiproliferative Agents for the Treatment of Cancer - Compounds of a certain formula (I), | 04-16-2009 |
20090098134 | COMPOSITIONS AND METHODS FOR INHIBITING ENDOGENOUS IMMUNOGLOBULIN GENES AND PRODUCING TRANSGENIC HUMAN IDIOTYPE ANTIBODIES - The invention relates to transgenic animals lacking endogenous Ig and capable of producing transgenic antibodies, as well as methods of making the same. The invention further relates to methods for producing transgenic antibodies in such animals, and transgenic antibodies so produced. | 04-16-2009 |
20090098135 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE - Combinations of PI3K inhibitor compounds having Formulas I and II and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hyperproliferative disorders such as cancer. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 04-16-2009 |
20090098136 | USE OF TNF RECEPTOR ANTAGONISTS FOR TREATING DRY EYE - Methods of treating dry eye by administering inhibitors of tumor necrosis factor α (TNFα) are disclosed. | 04-16-2009 |
20090098137 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER - A combination of an mTOR inhibitor compound with one or more pharmaceutically active agents, for simultaneous, concurrent, separate or sequential use for preventing or treating a proliferative disease. | 04-16-2009 |
20090098138 | DETECTION OF PROTEINS FROM CIRCULATING NEOPLASTIC CELLS - The protein EGFR, ERCC1, RRM1, thymidylate synthase, or beta-tubulin from cancer cells is detected in a blood sample by enriching the cancer cells from the blood sample followed by performing on the enriched cancer cells an immunoassay capable of detecting the proteins mentioned above. Cancer patients overexpressing EGFR are treated with an anti-EGFR agent, for example cetuximab, panitumumab, erlotinib or gefitinib. | 04-16-2009 |
20090110683 | MONOCLONAL ANTIBODIES AGAINST ACTIVATED PROTEIN C - The present invention provides monoclonal antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. Other antibodies inhibit both activated protein C and activation of unactivated protein C. Methods of treatment employing these antibodies are described herein as are methods of screening for and detecting these antibodies. | 04-30-2009 |
20090117124 | Anti-IgE antibodies - The present invention relates to novel human antibodies specifically directed against human immunoglobulin E (anti-IgE). The present invention also relates to pharmaceutical compositions and methods for treating asthma, in particular allergic asthma, as well as other IgE-mediated disorders including allergic rhinitis and food allergies. | 05-07-2009 |
20090117125 | SYNTHESIS OF 8H-3A-AZA-CYCLOPENTA[A]INDENES AND 5,10-DIHYDROPYRROLO[1,2-B]ISOQUINOLINES DERIVATIVES AND THEIR USE AS ANTITUMOR THERAPEUTIC AGENTS - The present disclosure relates to a series of bis(hydroxymethyl) and its bis(carbamate) of 8H-3a-azacyclopenta[a]indene-1-yl and 5,10-dihydropyrrolo-[1,2-b]isoquinolines derivatives (Formula I-Formula IV) as DNA di-alkylating agents. The preliminary antitumor studies indicated that compounds disclosed herein could exhibit potent cytotoxicity in vitro and antitumor therapeutic efficacy in human tumor xenografts and could have little or no cross-resistance to either Taxol or Vinblastine. The results demonstrated that compounds disclosed herein possess potent antitumor therapeutic efficacy and are expected to have potential for clinical applications. | 05-07-2009 |
20090130116 | Use of CEACAM8-Specific Substances for Treating Autoimmune Diseases and a Method for Screening Substances Which Induce Apoptosis - The invention relates to the use of substances which are specific to CEACAM8 for the manufacture of a medicament for the prophylactic or therapeutic treatment of human autoimmune diseases and/or gout. Another object of the invention concerns the use of CEACAM8-specific substances for apoptosis induction in-vitro. The invention also relates to a method for screening substances which induce apoptosis and a method for inducing apoptosis in human granulocytes. | 05-21-2009 |
20090130117 | Substituted Tetrazole Compounds and Uses Thereof - The present invention provides tetrazole compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising the tetrazole compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a compound of the present invention. | 05-21-2009 |
20090130118 | SCUTELLARIA BARBATA EXTRACT AND COMBINATIONS FOR THE TREATMENT OF CANCER - An extract of | 05-21-2009 |
20090136511 | Interleukin-15 Antagonist Peptide - Current invention is related to the molecular pharmacology branch particularly to a peptide belonging to the Interleukin-15 sequence (IL-15) which is able to inhibit IL-15 biological activity, analogues or mimetic of such peptides. In the current invention it is shown that the peptide inhibits both IL-15-induced T cells proliferation upon binding to the IL15 receptor α subunit (IL15Rα) and TNFα-mediated apoptosis. | 05-28-2009 |
20090136512 | CXCL13 Antagonists and Their Use for the Treatment of Inflammatory Diseases - Methods of treating disorders related to CXCL13 activity utilize CXCL13 antagonists and, optionally, TNFα antagonists, such as antibodies, including specified portions or variants, polypeptides, polynucleotides, siRNA, shRNA, ribozymes, and DNAzymes. Disorders related to CXCL13 activity include inflammatory disorders, such as pulmonary disorders, for example, asthma, emphysema, and COPD, and systemic lupus erythematosus. | 05-28-2009 |
20090136513 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS - A compound having formula (I): wherein: R, A, R | 05-28-2009 |
20090148458 | COAGULATION FACTOR III POLYMORPHISMS ASSOCIATED WITH PREDICTION OF SUBJECT OUTCOME AND RESPONSE TO THERAPY - The invention provides methods and kits for obtaining a prognosis for a subject having or at risk of developing an inflammatory condition or hypertension. The method generally comprises determining a coagulation factor III genotype(s) of a subject for one or more SNPs, comparing the determined genotype with known genotypes for the polymorphism that correspond with the ability of the subject to recover from the inflammatory condition and identifying subjects based on their prognosis. The invention also provides for methods of identifying potential subjects having an inflammatory condition who are more likely to benefit from treatment with an anti-inflammatory agent or anti-coagulant agent and subsequent to treatment recover from the inflammatory condition. The invention also provides for methods of treating such subjects with an anti-inflammatory agent or anti-coagulant agent based on the subject's genotype. | 06-11-2009 |
20090162372 | FIBRONECTIN ED-B ANTIBODIES, CONJUGATES THEREOF, AND METHODS OF USE - The present invention provides anti-ED-B antibodies, antibody fragments, and antibody mimetics and such antibodies conjugated to a partner molecule, wherein the antibody or the antibody-partner molecule conjugate provides a therapeutic effect regardless of whether the ED-B-antibody or ED-B-conjugate complex is internalized within a targeted cell. | 06-25-2009 |
20090169557 | Whole glucan particles in combination with antibiotics, vaccines and viral monoclonal antibodies - The present invention relates to compositions and methods of using whole glucan particles and agents. Whole glucan particles enhance the tumoricidal activity of the innate immune system by binding to the C3 complement protein receptor CR3. This binding enhances innate immune system cytotoxicity, as well as stimulating the release of activating cytokines and enhances the bodies response to the agent. | 07-02-2009 |
20090169558 | BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 - A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof: | 07-02-2009 |
20090169559 | Parenteral formulations of peptides for the treatment of systemic lupus erythematosus - The subject invention provides a pharmaceutical composition comprising: an aqueous carrier; from 0.1 mg/ml to 20 mg/ml of the composition of a pharmaceutically acceptable salt of a) a peptide comprising at least 12 and at most 30 consecutive amino acids having a sequence corresponding to (i) a sequence of amino acids found within a complementarity-determining region (CDR) of a heavy or a light chain of a human monoclonal anti-DNA 16/6 Id antibody, or (ii) a sequence of amino acids found within a complementarity-determining region (CDR) of a heavy or a light chain of a pathogenic anti-DNA monoclonal antibody that induces a systemic lupus erythematosus (SLE)-like disease response in mice, or b) a peptide comprising consecutive amino acids having the sequence shown by any of SEQ ID NOS. 8-17, or c) a peptide comprising consecutive amino acids having a sequence of any of a) and b), or at least two of the sequences in (a)(i), (a)(ii) and (b)(i) through (b)(x), or d) a peptide comprising consecutive amino acids having a sequence comprising at least two identical sequences included in (a)(i), (a)(ii) and (b)(i) through (b)(x); and a solubility enhancer, wherein both the peptide and the solubility enhancer are dissolved in the aqueous carrier; and wherein the composition has a pH between 4 and 9, and a method of alleviating symptoms of SLE in a human by administering an effective amount of the composition. | 07-02-2009 |
20090169560 | DISULFIDE, SULFIDE, SULFOXIDE, AND SULFONE DERIVATIVES OF CYCLIC SUGARS AND USES THEREOF - In the present invention there are disclosed new derivatives of dianhydrohexite mononitrate corresponding to formula (I), tautomers, pharmaceutically acceptable salts, prodrugs and solvates thereof: | 07-02-2009 |
20090175878 | Cerebral Vasospasm Inhibitor - An objective of the present invention is to provide a cerebral vasospasm inhibitor which is effective on cerebral vasospasm occurring after subarachnoid hemorrhage and has few side-effects. The cerebral vasospasm inhibitor of the invention is characterized in containing an anti-HMGB1 monoclonal antibody as an active ingredient. | 07-09-2009 |
20090175879 | NOVEL TARGET IN THE TREATMENT OF CYTOKINE RELEASE SYNDROME - A novel therapeutic and diagnostic target in the treatment of Cytokine Release Syndrome is provided. More specifically, a novel target is disclosed in the treatment of CRS occurring with diseases such as bacterial and viral infection as well as adverse reaction in drug therapy. | 07-09-2009 |
20090181031 | Antibodies to bufadienolides prevent inhibition of Na/K ATPase and prolong survival in shock - The present invention relates to compositions and methods of use thereof for treatment of clinical conditions manifested from and/or exacerbated by a decrease or an inhibition of Na/K ATPase activity. The invention relates to composition comprises monoclonal or polyclonal antibodies to bufalin and/or bufalin sulfate, or vaccination against bufalin and/or bufalin sulfate, which prevents or attenuates inhibition of Na/K ATPase activity thereby attenuating the adverse physiological effects of bufalin and/or bufalin sulfate inhibition. The invention also relates to methods of treating hemorrhagic, septic shock, cardiogenic shock, shock resulting from physical trauma, diabetes, mental depression, bipolar disorder and schizophrenia comprising administering a therapeutically effective amount of an bufalin monoclonal or polyclonal antibody. | 07-16-2009 |
20090181032 | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof - The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity. | 07-16-2009 |
20090186034 | Gene expression markers for inflammatory bowel disease - The present invention relates to methods of gene expression profiling for inflammatory bowel disease pathogenesis, in which the differential expression in a test sample from a mammalian subject of one or more IBD markers relative to a control is determined, wherein the differential expression in the test sample is indicative of an IBD in the mammalian subject from which the test sample was obtained. | 07-23-2009 |
20090186035 | BUCCAL, POLAR AND NON-POLAR SPRAY OR CAPSULE CONTAINING DRUGS FOR TREATING AN INFECTIOUS DISEASE OR CANCER - Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant. | 07-23-2009 |
20090191210 | Method for inhibiting tumor invasion or spreading in a subject - The present invention provides for a method for inhibiting tumor invasion or metastasis in a subject which comprises administering to the subject a therapeutically effective amount of a form of soluble Receptor for Advanced Glycation Endproducts (RAGE). The present invention also provides a method for evaluating the ability of an agent to inhibit tumor invasion in a local cellular environment which comprises: (a) admixing with cell culture media an effective amount of the agent; (b) contacting a tumor cell in cell culture with the media from step (a); (c) determining the amount of spreading of the tumor cell culture, and (d) comparing the amount of spreading of the tumor cell culture determined in step (c) with the amount determined in the absence of the agent, thus evaluating the ability of the agent to inhibit tumor invasion in the local cellular environment. The present invention also provides a pharmaceutical composition which comprises a therapeutically effective amount of the agent evaluated in the aforementioned method and a pharmaceutically acceptable carrier. | 07-30-2009 |
20090191211 | METHODS FOR DAMAGING CELLS USING EFFECTOR FUNCTIONS OF ANTI-EphA4 ANTIBODIES - The present invention relates to the use of cytoxicity based on the effector function of anti-EphA4 antibodies. Specifically, the present invention provides methods and pharmaceutical compositions that comprise an anti-EphA4 antibody as an active ingredient for damaging EphA4-expressing cells using antibody effector function. Since EphA4 is strongly expressed in pancreatic cancer cells, the present invention is particularly useful in pancreatic cancer therapies. | 07-30-2009 |
20090196874 | ANTI-TSG101 ANTIBODIES AND THEIR USES FOR TREATMENT OF VIRAL INFECTIONS - The invention involves the detection of virally infected cells by antibodies or antibody fragments which selectively bind to TSG101. TSG101 is on the surface of mammalian cells, and thus available for detection by antibodies, during viral budding—a phenomenon wherein viral particles escape a virally infected cell after propagation in that cell, so as to infect other cells. To achieve budding, a protein, TSG101 is “hijacked” and misdirected to, or mis-expressed on, the surface of the infected cell. Antibodies can be used to selectively detect such infected cells. Certain TSG101 antibodies may provide therapeutic benefit when administered to infected mammals. | 08-06-2009 |
20090202556 | ANTI-CLAUDIN-4 ANTIBODY - An object of the present invention is to provide a monoclonal antibody which is useful as a diagnostic agent or a therapeutic agent for a disease relating to a polypeptide encoded by Claudin-4 (hereinafter referred to as “CLDN4”) gene or a polypeptide encoded by a Claudin-3 (hereinafter referred to as “CLDN3”) gene, or a method for using the same. Accordingly, the present invention provides a monoclonal antibody or an antibody fragment thereof, which specifically recognizes three-dimensional structure of an extracellular region of CLDN4 and binds to the extracellular region; a monoclonal antibody or an antibody fragment thereof, which specifically recognizes three-dimensional structure of both of extracellular regions of CLDN3 and CLDN4 and binds to the extracellular regions; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which comprises the DNA; a transformant obtained by transforming the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a diagnostic agent or a therapeutic agent for a disease relating to a polypeptide encoded by CLDN4 gene and/or CLDN3 gene using the antibody or the antibody fragment. | 08-13-2009 |
20090202557 | Compositions and methods for crystallizing antibody fragments - The invention provides methods of crystallizing antibodies and fragments thereof as well as crystals produced thereby. More particularly, the invention provides methods of crystallizing human and non-human Fab fragments of antibodies, either alone or as co-crystals with their target ligand. For example, a crystal comprising a murine Fab fragment of the antibody 125-2H or a human Fab fragment of the antibody ABT-325, which bind to IL-18, are provided as well as a co-crystal of a murine Fab fragment bound to IL-18. ABT-325 and 125-2H differ significantly in combining site character and architecture, thus explaining their ability to bind IL-18 simultaneously at distinct epitopes. | 08-13-2009 |
20090208508 | NOVEL USE OF UBIQUITIN C-TERMINAL HYDROLASE-L1 - The present invention relates to a composition for diagnosing cancer metastasis comprising Ubiquitin C-terminal hydrolase-L1 (UCH-L1), a use of UCH-L1 for diagnosing cancer metastasis and a method for diagnosing cancer metastasis using the same; a composition for suppressing cancer metastasis comprising an inhibitor of UCH-L1, a use of an inhibitor of UCH-L1 for suppressing cancer metastasis and a method of suppressing cancer metastasis using the same; a composition for screening a cancer metastasis inhibitor comprising UCH-L1 protein, a use of UCH-L1 protein for screening a cancer metastasis inhibitor and a method of screening cancer metastasis inhibitor using the same; a composition for screening a cancer metastasis inhibitor comprising UCH-L1 gene, a use of UCH-L1 gene for screening a cancer metastasis inhibitor, a method of screening cancer metastasis inhibitor using the same. | 08-20-2009 |
20090214557 | BIOLOGICALLY ACTIVE ANTIBODIES RECOGNIZING A CELL SURFACE MOLECULE SELECTIVELY EXPRESSED ON LIVING MOUSE NATURAL TYPE ONE (I) INTERFERON PRODUCING CELLS - An isolated and characterized monoclonal antibody (“440 | 08-27-2009 |
20090214558 | NOVEL MAdCAM ANTIBODIES - The invention provides new, improved anti-MAdCAM antibodies. Uses of these antibodies in medicine are also included, in particular for the treatment of inflammatory conditions such as inflammatory bowel disease. | 08-27-2009 |
20090220516 | Neuroprotection of retinal ganglion cells - This invention relates to the neuroprotection of the optic nerve and the treatment of glaucoma, more specifically, the invention is directed to a method of preventing, inhibiting, decreasing incidence and suppressing death in ganglion cells by manipulating the P2X | 09-03-2009 |
20090220517 | METHOD FOR PRODUCING EPITOMERS AND THEIR USES ON CARRIER MICROORGANISMS - The present invention relates to a method for producing carrier microorganisms, in particular bacteria, which, through targeted genetic manipulation, carry epitopes or epitomers, respectively, on their surfaces. Epitomers are antigenically effective epitopes that can be found in the polypeptide chain in multiple identical copies, and which, when expressed on the surface of the bacteria, can be used for immunization with particular success. A further aspect relates to correspondingly produced bacteria and their uses as vaccines, in particular in cancer therapy. | 09-03-2009 |
20090220518 | METHODS AND COMPOSITIONS FOR TREATMENT OF GRAFT REJECTION AND PROMOTION OF GRAFT SURVIVAL - Embodiments herein illustrate methods of treating, reducing or preventing transplantation rejection and/or side effects associated with transplantation. Some embodiments relate to compositions and methods for inhibition of graft rejection and promotion of graft survival. Other embodiments relate to modulation of cellular activities, including graft rejection, promotion of graft survival, graft versus host rejection and conditions commonly associated with graft rejection. Yet other embodiments relate to the inhibitory compounds comprising naturally occurring and man-made inhibitors of serine protease, derivatives and fragments of the carboxy-terminus of alpha1-antitrypsin and inducers of other alpha1-antitrypsin activities and uses thereof. | 09-03-2009 |
20090220519 | ANTI-IL-22RA ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION - The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners. | 09-03-2009 |
20090232826 | Antibody or a fragment thereof, having neutralizing activity against hiv but not against il2 - The invention relates to a monoclonal antibody or a fragment thereof comprising in the H chain variable region at least one complementarity determining region (CDR) selected among CDR1, CDR2 and CDR3 having, respectively, an amino acids sequence set forth as SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3 or functional analogues thereof. | 09-17-2009 |
20090232827 | Compositions and methods of use of compounds to increase cancer patient survival time - The present invention discloses and claims compositions, methods of treatment, and kits which cause an increase in time of survival in cancer patients, wherein the cancer either: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions. The present invention also discloses and claims methods and kits for the administration of said compositions to properly treat cancer patients. Additionally, the present invention discloses and claims methods and kits for quantitatively determining the level of expression of thioredoxin or glutaredoxin in the cancer cells of a cancer patient, methods of using those determined levels in the initial diagnosis and/or planning of subsequent treatment methodologies for said cancer patient, as well as ascertaining the potential growth “aggressiveness” of the particular cancer and treatment responsiveness of the particular type of cancer. Further, the present invention discloses and claims novel pharmaceutical compositions, methods, and kits used for the treatment of patients with medical conditions and disease where there is the overexpression of thioredoxin and/or glutaredoxin, and wherein this overexpression is associated with deleterious physiological effects in the patients. | 09-17-2009 |
20090232828 | Methods of Using IGFIR and ABL Kinase Modulators - The invention provides methods of treating cancer with a compound which inhibits kinases, more specifically IGF1R and Abl, in combination with treatments(s) selected from surgery, radiation, monoclonal antibody, bone marrow or peripheral blood stem cell transplantation, and one or more chemotherapeutic agent(s). | 09-17-2009 |
20090246204 | USE OF A CD28 BINDING SUBSTANCE FOR MAKING A PHARMACEUTICAL COMPOSITION - The invention relates to the use of a CD28-specific superagonistic monoclonal antibody (mAb) or of a mimicry compound hereto for making a pharmaceutical composition for the induction and/or multiplication of regulatory T cells. | 10-01-2009 |
20090252738 | Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix - Compositions and methods useful in inhibiting proliferation of CA IX+preneoplastic or neoplastic cells in a mammal are provided. The compositions are antagonist anti-CA IX antibodies and other inhibitory agents that target carbonic anhydrase activity of CA IX on these cells. The antagonist anti-CA IX antibodies or antigen-binding fragments thereof are specifically reactive with an inhibitory epitope of CA IX or biologically active variant thereof. Formation of an antibody-antigen complex between the antagonist anti-CA IX antibodies or antigen-binding fragments thereof and the respective inhibitory epitopes results in inhibition of carbonic anhydrase activity of CA IX or biologically active variant thereof. Other small molecule agents that inhibit carbonic anhydrase activity of CA IX or biologically active variant thereof and screening assays for identifying such agents are also provided. The antagonist anti-CA IX antibodies, antigen-binding fragments thereof, and other CA IX inhibitory agents identified herein are useful in the treatment of cancers characterized by the expression of the CA IX tumor-associated antigen. | 10-08-2009 |
20090252739 | Cerebral Infarction Suppressant - An objective of the present invention is to provide a suppressant for cerebral infarction occurred after long-term ischemia associated with actual cerebral infarction, and has fewer side effects. The cerebral infarction suppressant of the present invention is characterized in comprising an anti-HMGB1 monoclonal antibody as an active ingredient. | 10-08-2009 |
20090252740 | Method for Predicting Responsiveness to TNF Alpha Blocking Agents - The invention provides an in vitro method for predicting whether a patient would be responsive to a treatment with a TNFα blocking agent, which method comprises determining the expression level of eight genes in a biological sample of said patient, wherein said genes are EPS15, HLA-DPB1, AKAP9, RASGRP3, MTCBP-1, PTNP12, MRPL22 and RPS28. The invention further provides a DNA chip for performing such method. | 10-08-2009 |
20090258024 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF CHRONIC INFLAMMATORY DISEASES - This invention relates to methods and compositions for diagnosis and treatment of chronic inflammatory diseases by blocking CD147 interaction with extracellular cyclophilin. Specifically, the methods and compositions of this invention regulate recruitment of leukocyte to the infection site by specifically blocking the CD147 domain involved with the chemotactic function without blocking the CD147 domain involved with EMMPRIN function. | 10-15-2009 |
20090263397 | Combination anti-cancer therapy - The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an anti-cancer agent or treatment that elevates pAkt levels in tumor cells and an IGF-1R kinase inhibitor of Formula (I) (e.g. OSI-906). Examples of such anti-cancer agents or treatments include doxorubicin, cisplatin, and ionizing radiation. The present invention also provides a pharmaceutical composition comprising an anti-cancer agent that elevates pAkt levels in tumor cells and an IGF-1R kinase inhibitor of Formula (I), in a pharmaceutically acceptable carrier. The present invention also provides a method of identifying tumor cells that will respond most favorably to treatment with a combination of an anti-cancer agent or treatment that elevates pAkt levels in tumor cells and an IGF-1R kinase inhibitor. | 10-22-2009 |
20090263398 | PHARMACEUTICAL COMBINATIONS - The invention provides a combination comprising an ancillary compound and a compound having the formula (0): or salts or tautomers or N-oxides or solvates thereof; wherein X is a group R | 10-22-2009 |
20090263399 | METHOD FOR ESTABLISHING THE SENSITIVITY OF TUMOURS TO CAPECITABIN AND TEST KIT - The invention relates to a method for establishing the sensitivity of tumors towards capecitabine, if applicable in combination with Docetaxel or Paclitaxel or the humanized antibody Herceptin, or COX-2 inhibitors or angiogenesis inhibitors and test kit. | 10-22-2009 |
20090263400 | OSTEOPOROSIS ASSOCIATED MARKERS AND METHODS OF USE THEREOF - Disclosed are methods of identifying subjects with osteoporosis or osteopenia, subjects at risk for developing osteoporosis, osteopenia, and bone fractures, methods of evaluating the effectiveness of osteoporosis treatments in subjects with osteoporosis or osteopenia, and methods of selecting therapies for treating osteoporosis or osteopenia, using biomarkers. | 10-22-2009 |
20090280128 | ANTI-ILT7 ANTIBODY - An antibody binding to IPC was obtained by using an animal cell in which a cell membrane protein associatable with ILT7 was co-expressed as an immunogen. The antibody of the invention has a high specificity which allows immunological distinction between other ILT family molecules and ILT7. The anti-ILT7 antibody of the invention bound to IPC and inhibited the activity thereof. With the anti-ILT7 antibody of the invention, the IPC activity can be inhibited and an interferon-related disease can be treated or prevented. ILT7 expression is maintained even in IPC in the presence of IFNα. Therefore, an inhibitory action of IPC activity by the anti-ILT7 antibody can be expected even in an autoimmune disease patient with an increased production of IFNα. | 11-12-2009 |
20090280129 | HIGH CONCENTRATION ANTIBODY AND PROTEIN FORMULATIONS - The present application relates to highly concentrated antibody and protein formulations with reduced viscosity that are stable, relatively isotonic and are of low turbidity. The formulations are particularly suitable for subcutaneous administration. The application further describes articles of manufacture containing such formulations and method for using them to treat disorders treatable by the formulated antibody or protein. | 11-12-2009 |
20090285824 | Compositions and methods relating to anti IGF-1 receptor antibodies - The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions. | 11-19-2009 |
20090285825 | NOVEL SNAKE TOXIN - This invention is in the field of snake venom and the invention provides a novel snake toxin protein and nucleic acids encoding the same. Also, provided are various uses and compositions based on the discovery of the novel snake toxin. | 11-19-2009 |
20090291085 | ANTIBODIES AGAINST ERBB3 AND USES THEREOF - The present invention provides a novel class of monoclonal antibodies which bind ErbB3 receptor and inhibits various ErbB3 functions. For example, the antibodies described herein are capable of binding to ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor. | 11-26-2009 |
20090291086 | Compositions and Methods for Treating Cerebral Thrombosis and Global Cerebral Ischemia - Modified annexin proteins, including heterodimers and homodimer of various human annexins, are provided for treatment of cerebral thrombosis and global cerebral ischemia. Also provided are phosphatidylserine (PS) binding proteins for treatment of cerebral thrombosis and global cerebral ischemia. The modified annexins and/or PS binding proteins bind PS on cell surfaces, thereby preventing the attachment of leukocytes and platelets to endothelial cells during post-ischemic reperfusion. By maintaining endothelial cell and vascular wall integrity PS binding proteins and/or modified annexin proteins decrease cerebral hemorrhage. Modified annexins and other PS binding proteins also suppress the production of mediators of edema, the extension of cerebral damage during reperfusion and the risk of rethrombosis. Thus, modified annexin proteins and/or other PS binding proteins decrease brain damage following cerebral thrombosis and global cerebral ischemia. | 11-26-2009 |
20090304703 | Compositions and methods for the diagnosis and treatment of immune disorders - The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. In particular, the invention describes a gene known in the art, alternatively, as ST2, T1 and Fit-1, and referred to herein as the 103 gene. The 103 gene is disclosed herein to be differentially expressed in TH2 cells and not in TH1 cells. Further, the 103 gene product is demonstrated herein to be an important modulator of TH2 and TH2-like immune response both in vitro and in vivo. Thus, the 103 gene, its gene products and antibodies that specifically bind thereto can be used diagnostically or as targets for therapeutic intervention in the treatment of a variety of immune disorders. | 12-10-2009 |
20090304704 | METHODS FOR DIAGNOSING AND PREDICTING NON-ALCOHOLIC STEATOHEPATITIS (NASH) - The invention provides a panel of genes useful for diagnosing non-alcoholic steatohepatitis (NASH). The invention also provides a method of diagnosing NASH in non-invasive assays based on the expression of particular genes in a panel of NASH-related genes. Methods of treatment for NASH and compositions for treating NASH are also provided. | 12-10-2009 |
20090311264 | Use of Disorazoles and Their Derivatives for the Treatment of Benign and Malignant Oncoses - The invention relates to disorazoles of the general formula I, which are employed as medicaments, preferably for the treatment of oncoses, in particular in the case of pharmaceutical resistance to other active compounds and in the case of metastasizing carcinoma. The possible uses are not restricted to oncoses. | 12-17-2009 |
20090317399 | Uses and compositions for treatment of CROHN'S disease - The invention provides methods, uses and compositions for the treatment of Crohn's disease. The invention describes methods and uses for treating Crohn's disease, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to induce and maintain remission of Crohn's disease in a subject. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment of Crohn's disease in a subject. | 12-24-2009 |
20100003260 | PHENYLPENTADIENOYL DERIVATIVES AND THEIR USE AS PAR 1 ANTAGONISTS - The present invention relates to compounds of general formula (I): wherein: R | 01-07-2010 |
20100003261 | AGONIST ANTI-TRK-C MONOCLONAL ANTIBODIES - The invention concerns agonist anti-trkC monoclonal antibodies which mimic certain biological activities of NT-3, the native ligand of trkC. The invention further concerns the use of such antibodies in the prevention andior treatment of cellular degeneration, including nerve cell damage associated with acute nervous cell system injury and chronic neurodegenerative diseases, including peripheral neuropathy. | 01-07-2010 |
20100008927 | Use of (S)-Roscovitine for Prevention and/or Treatment of Neurological Diseases - The present invention relates to the use of 6-(benzyl-amino)-2(S)-[[1-(hydroxymethyl) propyl]amino]-9-isopropylpurine) or at least one of its pharmaceutical acceptable salts for manufacturing a medication intended for the prevention and/or treatment of neurological diseases, in particular associated with neurological lesions. | 01-14-2010 |
20100008928 | AGENT FOR PREVENTING/TREATING CANCER - A human monoclonal antibody against a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 3, its partial peptide, or a salt thereof, is useful as an agent for preventing/treating cancer, etc., an apoptosis inducer of cancer cells, a growth inhibitor of cancer cells, a cytotoxic agent against cancer cells through a host defense mechanism mediated by the Fc region of an antibody, and so on. | 01-14-2010 |
20100015158 | METHOD FOR TREATING ATROPHIC AGE RELATED MACULAR DEGENERATION - Compositions and methods for treating dry age related macular degeneration (dry AMD) by administration to an intraocular location of an anti-neovascular agent (such as bevacizumab) in either a liquid or solid polymeric vehicle (or both), such as a biodegradable hyaluronic acid or PLGA (or PLA). | 01-21-2010 |
20100015159 | Compositions and methods for treating kidney disease - The present invention relates to methods and compositions for the prevention and treatment of renal damage. The invention provides protein-based renal therapeutic agents for administration to subjects in order to prevent or treat renal degeneration or damage. | 01-21-2010 |
20100015160 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING ENDOMETRIOSIS - Although TF is expressed on perivascular cells of normal tissues and in the adventitial layer of blood vessels, these cells are sequestered from contact with circulating fVII by the tight endothelial cell layer of the normal vasculature. Therefore, differential expression of TF by endometriotic tissue makes it a specific target for inhibiting or treating endometriosis. Similarly, overexpression of PAR-2 by endometrial tissue in women with endometriosis makes it a target for inhibiting or treating endometriosis. In one embodiment, interference with binding of fVII to TF or of the TF/fVIIa to PAR-2 is accomplished by providing one or more antagonists that reduce or inhibit binding of these proteins as described above. In another embodiment, the catalytic activity of PAR-2 or the TF/fVIIa complex is inhibited by providing one or more antagonists as disclosed above. In another embodiment, TF and/or PAR-2 expression is downregulated by providing one or more inhibitory nucleic acids including, but not limited to, ribozymes, triplex-forming oligonucleotides (TFOs), antisense DNA, external guide sequences (EGSs)f siRNA, and microRNA specific for nucleic acids encoding TF or PAR-2. TF and PAR-2 antagonists can also be provided in combination with other anti-angiogenic agents or other agents used to treat endometriosis, such as those described above. | 01-21-2010 |
20100021470 | MONOCLONAL ANTIBODY PRODUCTION BY EBV TRANSFORMATION OF B CELLS - A method for producing a clone of an immortalised human B memory lymphocyte, comprising the step of transforming human B memory lymphocytes using Epstein Barr Virus (EBV) in the presence of a polyclonal B cell activator. The method is particularly useful in a method for producing a clone of an immortalised human B memory lymphocyte capable of producing a human monoclonal antibody with a desired antigen specificity, comprising the steps of: (i) selecting and isolating a human memory B lymphocyte subpopulation; (ii) transforming the subpopulation with Epstein Barr Virus (EBV) in the presence of a polyclonal B cell activator; (iii) screening the culture supernatant for antigen specificity; and (iv) isolating an immortalised human B memory lymphocyte clone capable of producing a human monoclonal antibody having the desired antigen specificity. | 01-28-2010 |
20100021471 | CARBON NANOTUBE-BASED DRUG DELIVERY SYSTEMS AND METHODS OF MAKING SAME - The present invention includes a conjugates comprising a carbon nanotube with at least one covalently attached recognition module, and at least one covalently attached pharmaceutical compound or a precursor of the pharmaceutical compound, | 01-28-2010 |
20100028358 | Compositions and Methods for Controlling Tissue Factor Signaling Specificity - Compositions and methods for treating a disease dependent upon tissue factor/factor VIIa signaling in a mammalian subject is provided. The methods comprise administering an inhibitor of tissue factor signaling to the mammalian subject. The inhibitor is effective in reducing the incidence of disease in the mammalian subject. Also provided are methods of screening for modulators of tissue factor/factor VIIa signaling. | 02-04-2010 |
20100034825 | GENERATION OF A CANCER-SPECIFIC IMMUNE RESPONSE TOWARD MUC1 AND CANCER SPECIFIC MUC1 ANTIBODIES - The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis. | 02-11-2010 |
20100040625 | Pharmaceutical Compositions Containing Monoclonal Anti-Idiotypic Anti-Ca-125 Antibody and Aluminium Derivatives - The present invention refers to a pharmaceutical composition for parenteral administration as vaccine comprising a monoclonal antibody and as adjuvant an aluminium derivative. | 02-18-2010 |
20100040626 | METHODS FOR DETECTING AND TREATING ATTENTION-DEFICIT/HYPERACTIVITY DISORDER - The invention provides a method of determining a susceptibility of a subject for development of ADHD. The method comprises obtaining a sample from the subject, analyzing the sample for an ADHD susceptibility haplotype of LPHN3 receptor which is associated with at least one genetic marker selected from the group consisting of rs7678046, rs1901223, rs6813183, and rs1355368, and determining if the subject has a susceptibility to develop ADHD, whereby the presence of the haplotype having one or more of the genetic markers is indicative of a susceptibility to develop ADHD. The invention also provides methods of treating ADHD. | 02-18-2010 |
20100040627 | BAFF RECEPTOR (BCMA), AN IMMUNOREGULATORY AGENT - A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided. | 02-18-2010 |
20100040628 | INDOPROFEN DERIVATIVES FOR PROMOTING BONE GROWTH - The present invention provides a method of promoting bone growth in a subject in need thereof, by administering to the subject a therapeutically effective amount of a compound of Formula I. The present invention also provides methods for the treatment of renal disease and cancer. | 02-18-2010 |
20100047248 | METHODS OF PROCESSING COMPOSITIONS CONTAINING MICROPARTICLES - A method for processing multi-phasic dispersions is provided. The method comprises providing a multi-phasic dispersion including dispersed and continuous phases, providing one or more non-solvents comprising an aqueous solution containing at least one multivalent cation, exposing the multi-phasic dispersion to the non-solvent to form a suspension containing one or more liquid phases and the solid microparticles, and removing at least a portion of the resulting one or more liquid phases while retaining at least the microparticles, thereby removing at least a portion of the non-volatile material from the microparticles. | 02-25-2010 |
20100047249 | INHIBITION OF FcyR-MEDIATED PHAGOCYTOSIS WITH REDUCED IMMUNOGLOBULIN PREPARATIONS - The invention relates to pharmaceutical compositions for inhibiting FcγR-mediated phagocytosis comprising a reduced immunoglobulin inhibitor of FcγR-mediated phagocytosis, such as anti-D, in combination with a pharmaceutically acceptable carrier. The invention also relates to methods for treating or preventing an autoimmune or alloimmune disease comprising administering to a subject in need thereof a therapeutically effective amount of a reduced immunoglobulin inhibitor of FcγR-mediated phagocytosis. | 02-25-2010 |
20100055106 | METHODS FOR REGULATING COMPLEMENT CASCADE PROTEINS USING ASTROVIRUS COAT PROTEIN AND DERIVATIVES THEREOF - The present invention provides a method for modulating the complement cascade by depleting the plasma of the functional activity of complement proteins and thereby reducing or eliminating complement-mediated cell lysis. The invention provides a method for the therapeutic use of coat proteins and derivatives thereof from the Astroviradae family of viruses in the treatment of complement-mediated cell lysis and peptide mediators of inflammation. The invention provides a method for the therapeutic use of coat proteins and derivatives thereof from the Astroviradae family of viruses in the treatment of complement-mediated diseases. Methods are described herein where complement cascade, triggered by either the classical or alternative complement pathways, is prevented from effecting cell lysis and inflammation due to inhibition or depletion of one or more complement components in the serum following administration of astrovirus coat proteins or derivatives. | 03-04-2010 |
20100055107 | METHODS FOR PREVENTING HEMATOLOGICAL MALIGNANCIES AND GRAFT VERSUS HOST DISEASE BY ANTI-CD3 PRECONDITIONING - Graft versus host disease (GVHD) may be prevented, while preserving a beneficial by graft versus leukemia (GVL) effect, in a subject receiving an allogeneic hematopoietic cell transplant by preconditioning the subject with a CD3 modulator, such as an agonistic anti-CD3 antibody. More than one CD3 modulator may be administered at one time. This method may be performed alone or in conjunction with irradiation of the subject. The use of anti-CD3 to precondition a subject to reduce tissue release of chemokines and prevents tissue dendritic cell migration to draining lymph nodes is also provided. Anti-CD3 preconditioning may also be used to modulate host dendritic cells before hematopoietic cell transplantation. | 03-04-2010 |
20100068209 | ANTIBACTERIAL COMPOSITIONS FOR DRUG ADMINISTRATION - Non-toxic aqueous compositions are provided having antibacterial activity. Specifically, the invention provides aqueous alkyl glycoside or saccharide alkyl ester compositions which meet the antimicrobial effectiveness test criteria set forth in USP 31 <51> in preventing growth of specified bacteria and fungi. | 03-18-2010 |
20100068210 | COMPOSITIONS AND METHODS FOR THE PREVENTION OF OXIDATIVE DEGRADATION OF PROTEINS - The invention relates to pharmaceutical formulations comprising a protein and free methionine in combination with one or more compounds capable of preventing the oxidation of aromatic amino acid residues within a protein. More specifically, the invention relates to stabilized, pharmaceutically effective preparations of oxidation-sensitive therapeutic agents. The invention further relates to a method of inhibiting the oxidation of such therapeutic agents. | 03-18-2010 |
20100074902 | METHODS FOR HUMAN ALLOGRAFTING - A method of preparing a human recipient for a graft from a human which includes: administering donor peripheral blood progenitor cells to the recipient, and providing a minimally ablative. | 03-25-2010 |
20100080805 | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof - A composition-of-matter comprising an antibody or antibody fragment including an antigen-binding region capable of specifically binding an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen is disclosed. | 04-01-2010 |
20100086553 | ANTITUMOR AGENT - To provide a pharmaceutical agent or an antitumor agent useful for the treatment and/or prevention of gastrointestinal cancer, leukemia, pituitary tumor, small cell lung cancer, thyroid cancer, and neuroastrocytoma. The antitumor agent containing, as an active ingredient, a 1,5-benzodiazepine derivative represented by the following formula (1): | 04-08-2010 |
20100092474 | PHARMACEUTICAL COMBINATIONS - The invention provides combinations comprising (or consisting essentially of) one or more ancillary compound(s) and a compound of the formula (I): | 04-15-2010 |
20100092475 | TREATMENT METHOD USING EGFR ANTIBODIES AND SRC INHIBITORS AND RELATED FORMULATIONS - The present invention relates to the treatment of EGFR-mediated disease, particularly cancer by inhibiting or blocking EGFR and src in combination or simultaneously. The invention relates to treatment, prevention, or modulation of cancer, particularly EGFR-mediated disease, with one or more EGFR modulator and src inhibitor in combination. The invention further relates to the treatment of cancer with anti-EGFR antibodies and src inhibitors. Methods and compositions for treatment of cancer with the antibody anti-EGFR mAb806 in combination or series with a src inhibitor or src inhibitors are described. | 04-15-2010 |
20100092476 | PANCREATIC CANCER BIOMARKERS - The present invention provides a method of diagnosing, prognosing or screening for pancreatic cancer in a subject. The method may be carried out on a sample such as a blood or tissue sample collected from the subject. The is carried out by (a) detecting one or more markers in a biological sample of said subject, said markers selected from the markers set forth in Table 1 (e.g. one or more markers selected from the group set forth in Table 2, and/or the group consisting of ALCAM, TIMP-1, ICAM1, LCN2, REG1A, REG3, IGFBP4, TNFRSF1A and WFDC2); and (b) determining an altered level of said marker(s), said altered level indicating said subject may be afflicted with or at risk of developing pancreatic cancer. Kits useful for carrying out the methods are also described. | 04-15-2010 |
20100092477 | METHODS AND COMPOSITIONS FOR TREATING PROSTATE CANCER - A polypeptide comprising an androgen binding region, the androgen binding region capable of binding to an androgen at a sufficient affinity or avidity such that upon administration of the polypeptide to a mammalian subject the level of biologically available androgen is decreased. Specifically disclosed is an AR IgG1 Fc fusion protein, comprising the androgen binding domain of human androgen receptor and the Fc region of IgG. This fusion protein is used in the treatment of prostate cancer and testosterone flare. | 04-15-2010 |
20100092478 | MATERIALS AND METHODS FOR EVALUATING AND TREATING NEUROMYELITIS OPTICA (NMO) - The invention provides prognostic methods for evaluating the severity of NMO and NMO-associated diseases as well as methods of treating NMO and NMO-associated diseases. | 04-15-2010 |
20100092479 | Compositions and methods for treatment of viral diseases - The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E). | 04-15-2010 |
20100098699 | Methods of using LRR superfamily genes and proteins - The instant application provides methods and compositions for the treatment of inflammation, for modulating the activity or expression of proinflammatory cytokines, for increasing the rate of wound healing, for treating infection, and for treating septic shock. The invention provides lumican, or modulators thereof, as a therapeutic composition for the treatment of these disorders. | 04-22-2010 |
20100098700 | PHARMACEUTICAL COMPOSITIONS FOR BINDING SPHINGOSINE-1-PHOSPHATE - The present invention relates to compositions that comprise an anti-S1P monoclonal antibody, antibody fragment, or derivative in a carrier, particularly a buffered, hypertonic aqueous solution, as well as to kits containing such compositions, and methods for using such compositions for treatment of diseases and conditions associated with S1P. | 04-22-2010 |
20100098701 | Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases - Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders. | 04-22-2010 |
20100098702 | METHOD OF TREATING ANDROGEN INDEPENDENT PROSTATE CANCER - The present invention is directed to a method treating prostate cancer. The method comprises administering to a patient in need thereof at least one compound selected from N-methyl-Δ3,3′-dihydroindole-2,2′ diketone; N-1-(β-D-O-triacetyl-xylopranosyl)-Δ3,3′-dihydroindole-2,2′ diketone; and N-1-(β-D-O-triacetyl-xylopranosyl)-N′-methyl-Δ3,3′-dihydroindole-2,2′ diketone. Preferably the compound is in an amount sufficient to inhibit growth, invasion, and/or metastasis of prostate cancer cells. | 04-22-2010 |
20100098703 | DETERMINATION OF AM-BINDING PROTEINS AND THE ASSOCIATION OF ADRENOMEDULLIN (AM) THEREWITH - The present invention provides methods for the isolation, identification, and purification of adrenomedullin (AM)-binding proteins. Also, provided are methods for utilizing the purified AM-binding proteins, or functional portions thereof, to diagnose, treat, and monitor AM-related diseases, for example, diseases or disorders associated with abnormally elevated AM levels. In addition, the present invention provides a newly identified complex between AM and a specific AM-binding protein 1 (AMBP-1); which has been isolated and identified herein as factor H (fH). The invention also provides AM/AMBP complexes, particularly AM/FH complexes, and antibodies specifically reactive with this complexes. Further provided are methods for identifying and purifying complexes of AM and an AM binding protein using anti-AM/fH antibodies, and methods for treating conditions such as cancer or diabetes utilizing compositions comprising these antibodies. The present invention additionally provides methods for identifying antagonists agents that inhibit the function of AM, factor H, or the AM/factor H complex. The invention also provides methods for treating conditions such as cancer or diabetes using these antagonist agents. | 04-22-2010 |
20100119517 | Use of Anti-MAdCAM Antibodies for the Treatment of Coeliac Disease and Tropical Sprue - Use of anti-MAdCAM antibodies for the treatment of coeliac disease and tropical sprue The application relates to the use of an anti-MAdCAM antibody for the manufacture of a medicament for the treatment of coeliac disease and/or tropical sprue. Methods of treatment for coeliac disease and/or tropical sprue using a therapeutically effective amount of an anti-MAdCAM antibody are also included. | 05-13-2010 |
20100119518 | TARGET FOR BREAST CANCER THERAPY AND/OR DIAGNOSIS - The present invention relates to breast cancer and methods for identifying therapeutics and diagnosis. In general, methods for identifying therapeutic agents directed to calcium flow arc disclosed. Also provided arc methods for diagnosis of breast cancer and/or a predisposition to breast cancer and methods of treatment of breast cancer. The methods include identifying therapeutic agents which modulate a CRAC channel and/or a glycoprotein activator of a CRAC channel. Also provided arc diagnostic methods that ultilise a CRAC channel and/or a glycoprotein activator of a CRAC channel. | 05-13-2010 |
20100119519 | OPHTHALMIC DRUG DELIVERY SYSTEM AND METHOD - An ocular device comprising a delivery body configured for implanting within the capsular bag of a patient's eye, the delivery body containing an ocular therapeutic agent, the delivery body having a permeable exterior surface for delivering the therapeutic agent when implanted in the patient's eye. | 05-13-2010 |
20100143364 | Chimeric Antibodies, Compositions and Methods for Treating Cocaine-Related Disorders - The invention relates to antibodies, including chimeric monoclonal antibodies, and fragments thereof, that bind to cocaine. The invention also relates to the use of these or any anti-cocaine antibodies, derivatives or variants in the prevention or treatment of cocaine-related disorders and in the amelioration of one or more symptoms associated with a cocaine-related disorder. | 06-10-2010 |
20100143365 | METHODS AND MATERIALS RELATED TO ANTI-AMYLOID ANTIBODIES - This document provides methods and materials related to anti-amyloid antibodies. For example, anti-amyloid antibodies, methods for making anti-amyloid antibodies, and methods for using an anti-amyloid antibody to treat or prevent an amyloid condition (e.g., AD) are provided. | 06-10-2010 |
20100143366 | ANTITUMOR AGENT - To provide a pharmaceutical agent or an antitumor agent useful for the treatment and/or prevention of gastrointestinal cancer, leukemia, pituitary tumor, small cell lung cancer, thyroid cancer, and neuroastrocytoma. The antitumor agent containing, as an active ingredient, a 1,5-benzodiazepine derivative represented by the following formula (1): | 06-10-2010 |
20100150931 | NOVEL RECEPTOR FOR CD40L AND USES THEREOF - The present invention relates to a novel CD40L receptor and its related activities. Methods, uses, reagents and kits for the modulation of CD40L activities related to its interaction with the novel receptor are disclosed. Also disclosed are therapeutic uses of reagents in treating CD40L-related disorders. | 06-17-2010 |
20100166762 | METHOD OF TREATING A PATHOLOGICAL SYNDROME - A method of treating disorder or condition that relates to intracellular signal transmission of a neurotransmitter, comprising administration of an homeopathically potentized form of antibodies to an antigen, which antigen is a molecule capable of effecting the intracellular signal transmission of a neuroreceptor, in particular dopamine or serotonin. | 07-01-2010 |
20100166763 | METHOD FOR DETERMINING THE IMMUNOGENICITY OF AN ANTIGEN - The present invention relates to methods for preparing an artificial immune system. The artificial immune system comprises a cell culture comprising T cells, B cells and antigen-primed dendritic cells. The artificial immune system of the present invention can be used for in vitro testing of vaccines, adjuvants, immunotherapy candidates, cosmetics, drugs, biologics and other chemicals. | 07-01-2010 |
20100172911 | Methods and Vectors for Generating Asialylated Immunoglobulins - The properties of an Fc-containing protein, for example, an antibody, are controlled by altering the sialylation of the oligosaccharides in the Fc region by transfecting the cell line expressing the Fc-containing protein with a vector sequence encoding a sialidase. The modified Fc-containing proteins have therapeutic utility in diseases or conditions in which it is desirable to control the affinity for one or more of the FcγRI, FcγRIIA, and FcγRIIIA receptors, ADCC activity, macrophage or monocyte activation, serum half-life, and avidity. | 07-08-2010 |
20100183620 | COMPOSITIONS AND METHODS FOR REGULATING COLLAGEN AND SMOOTH MUSCLE ACTIN EXPRESSION BY SERPINE2 - The invention encompasses methods and compositions for increasing or decreasing collagen 1A1 expression and/or α-smooth muscle actin expression in lung fibroblasts using SERPINE2 and antagonists of SERPINE2. The invention also encompasses methods and compositions for increasing or decreasing the formation of myofibroblasts. The invention further provides methods and compositions for treatment of lung diseases, such as idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. | 07-22-2010 |
20100189721 | ANTIBODY FORMULATIONS - This invention relates to a shear and temperature stable antibody formulations that are more stable than compared to a standard formulation (such as 30 mM citrate, 100 mM NaCl, pH 6.5). The present invention's shear and temperature stable antibody formulations show reduced precipitation when subjected to stress conditions but the standard formulation had aggregated. This result was unpredictable because thermodynamically the two formulations are similar as seen by their DSC (differential scanning calorimeter) profiles. | 07-29-2010 |
20100196385 | TARGETED BINDING AGENTS DIRECTED TO DLL4 AND USES THEREOF 524 - The invention relates to targeted binding agents against DLL4 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to DLL4. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of DLL4 and as diagnostics. | 08-05-2010 |
20100196386 | LIGANDS OF HVEM FOR TREATING HEMATOLOGIC MALIGNANCIES AND AUTOIMMUNE DISEASES - The present invention relates to ligands of HVEM for the treatment of hematologic malignancies, in particular Chronic lymphocytic leukaemia, and for the treatment of autoimmune diseases. | 08-05-2010 |
20100196387 | Disulfide, Sulfide, Sulfoxide, and Sulfone Derivatives of Cyclic Sugars and Uses Thereof - In the present invention there are disclosed new derivatives of dianhydrohexite mononitrate corresponding to formula (I), tautomers, pharmaceutically acceptable salts, prodrugs and solvates thereof: | 08-05-2010 |
20100203058 | DIAGNOSTICS AND THERAPEUTICS BASED ON CIRCULATING PROGENITOR CELLS - Methods and compositions for detection, diagnosis, and therapeutics of arterial diseases based on pro-angiogenic and non-angiogenic circulating hematopoietic stem and progenitor cells (CHSPCs) and circulation endothelial colony forming cells (ECFCs) are described. | 08-12-2010 |
20100203059 | METHOD OF TREATING A PATHOLOGICAL SYNDROME AND A PHARMACEUTICAL AGENT - A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms of formation of this particular pathological syndrome. | 08-12-2010 |
20100209431 | METAL TRIANGULO COMPOUND AND METHODS OF USING THE SAME - The present invention relates to a metal triangulo compound. Provided is also a method of inducing apoptosis in a cell that comprises administering the metal triangulo compound. Provided is also a method of preventing carcinogenesis in a cell that comprises administering the metal triangulo compound. | 08-19-2010 |
20100215660 | KRUPPEL-LIKE FACTORS AND FAT REGULATION - Disclosed herein are methods and cell lines used in fat regulation. The methods and cell lines incorporate Krüppel-like factors including, without limitation, klf-1 and klf-3. | 08-26-2010 |
20100215661 | NICOTINAMIDE DERIVATES USEFUL AS P38 INHIBITORS - Compounds of formula (I): | 08-26-2010 |
20100226925 | Homogeneous Antibody Populations - The present invention is generally directed to methods of producing an increase in the enrichment and/or recovery of preferred forms of monoclonal antibodies. More particularly, the invention relates to methods for eliminating disulfide heterogeneity in the hinge region of recombinant IgG2 antibody proteins. | 09-09-2010 |
20100226926 | Method of Detection of Fluorescence-Labeled Probes Attached to Diseased Solid Tissue - Disclosed herein, in certain embodiments, is a method of treating breast cancer characterized by the amplification of HER2 genes in a subject in need thereof, comprising: (a) isolating a tissue sample comprised of a plurality of breast tumor cells; (b) isolating a first section from said tissue sample; (c) isolating a second section from an adjacent portion of said tissue sample; (d) contacting the first section with a first stain; (e) contacting the second section with a probe; (f) imaging the first section following contact with the stain to produce a first image; (g) analyzing the first image for abnormal microscopic features; (h) identifying areas of interest in the first image that display abnormal microscopic features; (i) electronically annotating the first image to identify the areas of interest; (j) imaging the second section following contact with the probe; (k) aligning the first image and the second image; and (l) analyzing areas of interest in the second image that correspond to an area of interest identified in the first image; wherein the subject is administered an anti-HER2 antibody if HER2 is amplified or providing an alternative treatment if HER2 is not amplified. | 09-09-2010 |
20100233178 | USE OF ANTIBODIES FOR THE VACCINATION AGAINST CANCER - Described is the use of antibodies which are directed against human cellular membrane antigens for the vaccination against cancer diseases. | 09-16-2010 |
20100239588 | THE FUNCTIONAL EPITOPE OF OSTEOPONTIN, THE ANTI-OSTEOPONTIN MONOCLONAL ANTIBODY AND USE THEREOF - The present invention discloses the functional epitope of osteopontin; the anti-osteopontin monoclonal antibody and immune conjugate raising against the functional epitope and their use for preparing anti-tumor drug. The present invention also discloses the DNA sequence encoding the monoclonal antibody, the vector and host cell containing the DNA sequence. The monoclonal antibody and immune conjugate of present invention can also be used to detect OPN. Through inhibiting OPN, the monoclonal antibody or immune conjugate of present invention can remedy or respite autoimmune diseases and protect correlative tissues, so they can be used to remedy autoimmune diseases. | 09-23-2010 |
20100247544 | Compositions and Methods for Promoting the Healing of Tissue of Multicellular Organisms - Compositions are provided for promoting healing of tissue of a vertebrate organism. The compositions can be for internal administration of a therapeutically effective amount of pharmacologically active, protease inhibiting, aqueous media soluble polysulfonated materials in salt form and associated with a secondary material to reduce one or more of inflammation, bacterial proliferation, proteolytic activity, and cancerous cell growth. The compositions may additionally or alternatively be cross-linked so as to alter the solubility of these pharmacologically active salts or slow dissolution by providing biodegradable cross-linkers. Compositions for healing the tissue of a multicellular organism are provided that can include a polysulfonated material in a liquid mixture, as solid particles or constructs that may or may not biodegrade or deliver a pharmacologically relevant value. Some of the compositions are also provided for inclusion into a device for preventing infection, reducing inflammation, and preserving the activity of a protein or protein drug. | 09-30-2010 |
20100260765 | TARGETED BINDING AGENTS DIRECTED TO KDR AND USES THEREOF - 035 - The invention relates to targeted binding agents against KDR and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to KDR. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of KDR and as diagnostics. | 10-14-2010 |
20100266602 | Method for Diagnosing Rheumatoid Arthritis via Assaying Myofibroblast-Like Synoviocytes for Fibroblast Activation Protein - The invention relates to methods for diagnosing rheumatoid arthritis by assaying for Fibroblast Activation Protein Alpha expression in rheumatoid, myofibroblast like synoviocytes. Therapeutic aspects are also a part of the invention. | 10-21-2010 |
20100266603 | Monoclonal Antibody Specific to Ochratoxin A - This invention provides a monoclonal antibody specific to ochratoxin A and methods of assaying the level of ochratoxin A in food and feed. | 10-21-2010 |
20100278833 | THIOPHENE-IMIDAZOPYRIDINES - The invention relates to thiophene-imidazopyridine compounds according to formula (I), wherein the substituents and symbols are as defined in the description. The compounds are inhibitors of PIk1. | 11-04-2010 |
20100291097 | MONOCLONAL ANTIBODY - The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies that specifically recognize and bind to specific epitopes from a range of β-amyloid proteins. The antibodies of the present invention are particularly useful for the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system, particularly those ocular diseases associated with amyloid-beta-related pathological abnormalities/changes in the tissues of the visual system. | 11-18-2010 |
20100297137 | Hematopoietic Lineage Cell Specific Protein (HS1) as a Marker for Lymphoid Malignancy - Use of a phosphorylated form of hematopoietic-lineage-cell-specific-protein-1 (HS1) as a prognostic or diagnostic marker for a Lymphoid Malignancy, a disease in which B cell receptor stimulation is dysregulated or disease characterised by B lymphocyte proliferation. | 11-25-2010 |
20100310570 | MAPC TREATMENT OF BRAIN INJURIES AND DISEASES - The invention relates to the treatment of various injuries, disorders, dysfunctions, diseases, and the like of the brain with MAPCs, particularly in some aspects, to the treatment of the same resulting from hypoxia, including that caused by systemic hypoxia and that caused by insufficient blood supply. In some further particulars the invention relates, for example, to the treatment of hypoxic ischemic brain injury with MAPCs, in children for example, and to the treatment of cortical infarcts and stroke with MAPCs in adults, for example. | 12-09-2010 |
20100310571 | USES OF MONOCLONAL ANTIBODY 8H9 - This invention provides a composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a suitable carrier. This invention provides a pharmaceutical composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a pharmaceutically acceptable carrier. This invention also provides an antibody other than the monoclonal antibody 8H9 comprising the complementary determining regions of monoclonal antibody 8H9 or a derivative thereof, capable of binding to the same antigen as the monoclonal antibody 8H9. This invention provides a substance capable of competitively inhibiting the binding of monoclonal antibody 8H9. This invention also provides an isolated scFv of monoclonal antibody 8H9 or a derivative thereof. This invention also provides the 8H9 antigen. This invention also provides a method of inhibiting the growth of tumor cells comprising contacting said tumor cells with an appropriate amount of monoclonal antibody 8H9 or a derivative thereof. | 12-09-2010 |
20100322939 | NOVEL METHODS FOR TREATING EGFR-ASSOCIATED TUMORS - The invention relates to a method for the treatment of an EGFR-associated tumor comprising administration, to an individual in need thereof, of an anti-EGFR antibody in combination with radiotherapy and a radiosensitising agent. In one embodiment, the treatment further comprises administration of a chemotherapeutic agent. | 12-23-2010 |
20100322940 | IN VITRO MODIFICATION OF GLYCOSYLATION PATTERNS OF RECOMBINANT GLYCOPEPTIDES - This invention provides methods for modifying glycosylation patterns of glycopeptides, including recombinantly produced glycopeptides. Also provided are glycopeptide compositions in which the glycopeptides have a uniform glycosylation pattern. | 12-23-2010 |
20110020359 | METHODS AND COMPOSITIONS FOR TREATING NEURONAL DAMAGE OR DEGENERATION - This invention provides methods and compositions for reducing chondroitin-sulfate-proteoglycan-mediated inhibition of neuronal growth. The methods and compositions provided herein are particularly useful for treatment of neuronal damage or degeneration. | 01-27-2011 |
20110033474 | INHIBITION OF PLATELET AGGREGATION - The present invention provides methods and compositions for preventing platelet aggregation and for treating individuals suffering from conditions or undergoing procedures that may result in unwanted platelet aggregation. In particular the invention provides to methods and compositions for arterial vessel pacification. The methods are based on the administration of a therapeutically effective amount of a glycoprotein IIb/IIIa receptor antagonist, e.g., xemilofiban. The treatment may commence prior to a medical or surgical procedure or an outbreak of a condition, either of which results in the activation of platelets that may lead to thrombus formation, and may continue thereafter. | 02-10-2011 |
20110033475 | USE OF BETA-GLUCANS AGAINST BIOLOGICAL WARFARE WEAPONS AND PATHOGENS INCLUDING ANTHRAX - The present invention provides a means to broadly protect the military and the public from injury from biological warfare weapons, particularly infective agents such as anthrax. Beta (1,3)-glucans, particularly whole glucan particles, PGG-Glucan, and microparticulate glucan, provide general immune enhancement, thereby increasing the body's ability to defend against a wide variety of biological threats. Beta (1,3)-glucans have been shown to increase the resistance to infection by anthrax and other infectious organisms when administered before and after infection. The anti-infective mechanism of β(1,3)-glucan appears to involve stimulation of the innate immune system through increased cytokine release and CR3 receptor activation. Beta (1,3)-glucan is pharmaceutically stable, relatively compact, and can also be used without significant side effects. Beta (1,3)-glucan can also enhance the effectiveness of other medical countermeasures such as antibiotics, vaccines, and immune antibodies. | 02-10-2011 |
20110038873 | MEANS AND METHODS FOR TREATING OR PREVENTING BRAIN TUMORS BASED ON THE NUCLEAR RECEPTOR TAILLESS (TLX) - The present invention relates to the use of an inhibitor of tailless gene expression or tailless protein activity for the preparation of a pharmaceutical composition for treating or preventing the brain tumor in a subject. Preferably an inhibitor of tailless expression is a single or double stranded RNA. An inhibitor of tailless protein activity is preferably an antibody which specifically binds thereto. Finally, the invention includes methods for identifying anti-brain tumor drugs. | 02-17-2011 |
20110044990 | ANTIBODY DESIGN USING ANTI-LIPID ANTIBODY CRYSTAL STRUCTURES - The present invention provides crystalline forms of an anti-lipid antibody or fragment thereof, which may further comprise a lipid ligand of said antibody and/or salts, metals, or co-factors. Methods for making such crystals and co-crystals are provided. The lipid may be a bioactive lipid, including sphingolipids such as S1P. X-ray coordinates of such a crystal are provided, as are methods of using this information in antibody design or optimization. Methods for designing a humanized antibody to a lipid are provided. These methods may be performed in silico and may be intended to enhance binding affinity of an antibody to its original target lipid, and/or to alter binding specificity. Antibodies produced by these methods are also provided. | 02-24-2011 |
20110052593 | BREAST CANCER ASSOCIATED ANTIGEN - The invention relates to nucleic acid and amino acid sequences encoding BUC11 (SEQ ID NO: 36), BUC6 (SEQ ID NO: 31), BUC9 (SEQ ID NO: 32), and BUC10 (SEQ ID NO: 35), and to the use of such sequences in the identification and treatment of cancers. | 03-03-2011 |
20110059097 | MFAP4 as a Marker For Regulatory Cells and Anti-Cancer Cells - The present application provides a novel antibody that is specific for MFAP4. The application also provides methods and uses of MFAP4 as a marker for regulatory cells and/or anti-cancer cells. Further, the application provides methods and uses of MFAP4 binding agents for selection and activation of regulatory cells and/or anti-cancer cells. | 03-10-2011 |
20110070238 | CYTOTOXIC ANTI-LAG-3 MONOCLONAL ANTIBODY AND ITS USE IN THE TREATMENT OR PREVENTION OF ORGAN TRANSPLANT REJECTION AND AUTOIMMUNE DISEASE - Cytotoxic anti-LAG-3 monoclonal antibodies or fragments thereof causing depletion of LAG-3 | 03-24-2011 |
20110086037 | METHOD OF TREATING INFLAMMATORY DISORDERS - A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms of formation of this particular pathological syndrome. | 04-14-2011 |
20110097334 | Novel Marker Genes for Regulatory T Cells from Human Blood - The present invention provides novel marker genes for the specific identification and characterization of human suppressive and/or regulatory T cells including natural, adaptive, and expanded CD4 | 04-28-2011 |
20110097335 | ABC TRANSPORTER PROTEIN EXPRESSION INHIBITOR - Provided is a novel drug which exhibits excellent effect of inhibiting expression of an ABC transporter protein, as well as improved safety. | 04-28-2011 |
20110104173 | INHIBITION OF DEGRADATION OF EXTRACELLULAR MATRIX - This application relates to a method of inhibiting the degradation of an extracellular matrix associated with islet beta cells, said method comprising contacting said extracellular matrix with an effective amount of a heparanase inhibitor. | 05-05-2011 |
20110123540 | POTENT MUCOSAL IMMUNE RESPONSE INDUCED BY MODIFIED IMMUNOMODULATORY OLIGONUCLEOTIDES - The invention relates to the therapeutic use of immunostimulatory oligonucleotides and/or immunomers on mucosal innate immunity as well as adjuvant activity using ovalbumin (OVA) as an antigen through administration to the mucosal lining. | 05-26-2011 |
20110129480 | ANTI-FERROPORTIN 1 MONOCLONAL ANTIBODIES AND USES THEREOF - Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of human FPN1, and which are effective in maintaining or increasing the transport of iron out of mammalian cells and/or maintaining or increasing the level of serum iron, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a subject in vivo. | 06-02-2011 |
20110206679 | New Therapeutic and Diagnostic Methods for Alzheimer's Disease - The invention relates to diagnosing the presence or absence of antibodies, such as IgM, IgG or IgA antibodies, related to increased or decreased risk of developing Alzheimer's disease, using a phosphorylcholine conjugate. In addition, the invention relates to methods of immunization and prophylaxis, prevention and/or treatment of a subject against Alzheimer's disease, the method comprising the step of administering to the subject a pharmaceutical composition comprising at least one phosphoryl-choline conjugate, or the step of administering to the subject an antibody preparation, for example a monoclonal antibody, with reactivity to a phosphorylcholine and/or a conjugate thereof. | 08-25-2011 |
20110217308 | Compositions and methods using recombinant MHC molecules for the treatment of stroke - Two-domain MHC polypeptides are useful for modulating activities of antigen-specific T-cells, including for modulating pathogenic potential and effects of antigen-specific T-cells. Exemplary MHC class II-based recombinant T-cell ligands (RTLs) of the invention include covalently linked β1 and α1 domains, and MHC class I-based molecules that comprise covalently linked α1 and α2 domains. These polypeptides may also include covalently linked antigenic determinants, toxic moieties, and/or detectable labels. The disclosed polypeptides can be used to target antigen-specific T-cells, and are useful, among other things, to detect and purify antigen-specific T-cells, to induce or activate T-cells, to modulate T-cell activity, including by regulatory switching of T-cell cytokine and adhesion molecule expression, to treat conditions mediated by antigen-specific T-cells, including treatment and/or prevention of central nervous system damage relating to stroke. | 09-08-2011 |
20110229484 | Host Cell Kinases as Targets for Antiviral Therapies Against HCV Infection - The present invention provides several networks of cellular protein kinases as potential targets for medical intervention against hepatitis C virus (HCV) infection and HCV-related diseases and disorders in mammals, including humans. The invention relates to therapeutic protocols and pharmaceutical compositions designed to inhibit the activity of one or more of these protein kinases for the prevention and/or treatment of infections and diseases caused by HCV. The invention also relates to methods for the identification of kinase inhibitors that may be used to treat and/or prevent HCV infections and HCV-related diseases. | 09-22-2011 |
20110236391 | METHOD FOR OBTAINING AN EXCIPIENT-FREE ANTIBODY SOLUTION - The present invention relates to a method of ultra- and dialfiltrating an antibody solution containing at least one solute in addition to the antibody, which comprises diafiltrating the antibody solution with a solvent and bringing said mixture into contact with a semi-permeable membrane so as to allow the at least one solute present in the antibody solution and having a molecular weight lower than the molecular weight cut-off of the membrane to pass through the membrane, whilst retaining the antibody so that a modified antibody solution is obtained that only contains the antibody and the solvent. | 09-29-2011 |
20110274695 | PRODRUGS CONTAINING NOVEL BIO-CLEAVABLE LINKERS - The invention provides the compounds of formula (I) or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutical compositions comprising one or more compounds of formula I or intermediates thereof and one more of pharmaceutically acceptable carriers, vehicles or diluents. The invention further provides methods of preparation and methods of use of prodrugs including NO-releasing prodrugs, double prodrugs and mutual prodrugs comprising the compounds of formula I. | 11-10-2011 |
20110293625 | INHIBITION OF VEGF-A SECRETION, ANGIOGENESIS AND/OR NEOANGIOGENESIS BY SINA MEDIATED KNOCKDOWN OF VEGF-C AND RHOA - The invention relates to the use of short interfering nucleic acid molecules (siNAs, such as siRNAs) that modulate the expression of VEGF-C and/or RhoA involved in neovascular angiogenesis. In the present invention, inhibition of VEGF-C and/or RhoA gene expression lead to decreased expression of VEGF-A, which is required for initiation and the sustaining of angiogenesis. Further, the invention also relates to the inhibition of RhoA expression levels along with VEGF-C, so as to derive the benefits of down-regulating two different targets required for angiogenesis. The present invention describes compounds, compositions and methods useful for inhibition of neoangiogenesis. In certain embodiments, the invention relates to methods for inhibiting neovascularization, as well as compounds, such as VEGF-C and RhoA siRNAs, useful in the treatment of ocular disorders such as age related maculardegeneration (AMD), diabetic retinopathy, glaucoma and other neovascular disorders. | 12-01-2011 |
20110300150 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE - Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of autoimmune disease, inflammatory disease, or cancer. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates. | 12-08-2011 |
20110311544 | Anti-cd71 Monoclonal Antibodies and Uses Thereof for Treating Malignant Tumor Cells - The present invention provides novel anti-CD71 monoclonal antibodies, in particular mouse-human chimeric anti-CD71 monoclonal antibodies, advantageously associated to effector cells for triggering ADCC mechanisms. Anti-CD71 antibodies, as well as pharmaceutical compositions containing them, are useful for inhibiting proliferation and/or killing malignant tumour cells, especially metastatic cutaneous and uveal melanoma cells. | 12-22-2011 |
20110311545 | FAMILY OF PAIN PRODUCING SUBSTANCES AND METHODS TO PRODUCE NOVEL ANALGESIC DRUGS - A method may include treating pain, shock, and/or inflammatory conditions in a subject. A method may include using a therapeutically effective amount of an antibody, a lipoxygenase inhibitor, a cytochrome P-450 enzyme inhibitor, and/or an antioxidant configurable to at least partially treat pain, shock, and/or inflammatory conditions in a subject. A method of treating pain, shock, and/or inflammatory conditions in a subject may include inactivating or preventing at least one linoleic acid metabolite to treat certain conditions (e.g., pain, shock, and/or inflammation). | 12-22-2011 |
20120020979 | METHODS FOR TREATING IgE-MEDIATED DISORDER - This invention relates to methods of treating IgE mediated disorders such as allergy and asthma based on activating surface-bound IgD molecules on basophils. The invention also relates to methods of making IgD, as well as methods of screening for antimicrobial agents from IgD-activated basophils. | 01-26-2012 |
20120039895 | PHOSPHORYCHOLINE CONJUGATES AND CORRESPONDING ANTIBODIES - In subjects with hypertension, increases in intima-media thickness (IMT) at four years were less in subjects also having high autoantibodies particularly IgM, to phosphorylcholine. The presence or absence of autoantibodies, particularly IgM, against phosphrylcholine is thus related to an increased or decreased risk of developing ischemic cardiovascular diseases. A method to determining antibodies, particularly IgM antibodies, toward phosphorylcholine is proposed in this invention to identify subjects at risk of developing ischemic cardiovascular diseases. Animal experiments show that medium to high levels of antibodies, particularly IgM antibodies, can be detected in plasma after active immunization with a keyhole limpet hemocyanin (KLH)-phosphorylcholine conjugate. Pharmaceutical compositions comprising a phosphorylcholine conjugate or antibody preparations, for example a monoclonal antibody, with specificity to a phosphorylcholine conjugate is proposed as is use of these compositions as active or passive immunogens in the treatment or prevention of atherosclerosis. | 02-16-2012 |
20120039896 | METHOD FOR INHIBITING CELLULAR ACTIVATION BY INSULIN-LIKE GROWTH FACTOR-1 - A method of inhibiting cellular activation by Insulin-like Growth Factor-1 (IGF-1) in a subject in need thereof (e.g., a subject afflicted with cancer, atherosclerosis, diabetic retinopathy or other disease) comprises administering an antagonist that inhibits the binding of IAP to SHPS-1 to the subject in an amount effective to inhibit cellular activation by IGF-1. Compounds and compositions for carrying out such methods are also described. | 02-16-2012 |
20120045441 | METHODS OF TREATING LUNG DISEASE AND OTHER INFLAMMATORY DISEASES - A method of treating an inflammatory disease in a subject in need thereof is carried out by administering the subject a gastrin-releasing peptide (GRP) inhibitor in a treatment effective amount. Suitable GRP inhibitors include compounds of the general formula (I) and pharmaceutically acceptable salt or prodrugs thereof. | 02-23-2012 |
20120058120 | Targets for Growth Factor Signalling and Methods of Therapy - Methods of screening or designing therapeutic agents effective for the treatment of a transglutaminase-associated disease, disorder and/or condition are provided which include determining whether a candidate agent can modulate an interaction between a transglutaminase and an insulin-like growth factor and/or a member of the IGF family of receptors. Also provided are pharmaceutical compositions and methods of treatment using said pharmaceutical compositions. | 03-08-2012 |
20120070441 | EXTRACELLULAR YALURONIDASE FROM STREPTOMYCES KOGANEIENSIS - The invention relates to | 03-22-2012 |
20120100148 | ANTI-FERROPORTIN 1 MONOCLONAL ANTIBODIES AND USES THEREOF - Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of human FPN1, and which are effective in maintaining or increasing the transport of iron out of mammalian cells and/or maintaining or increasing the level of serum iron, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a subject in vivo. | 04-26-2012 |
20120100149 | Injectable, Non-Aqueous Suspension with High Concentration of Therapeutic Agent - An injectable, nonaqueous suspension including at least one therapeutic agent suspended in a single component vehicle. The single component vehicle is a single amphiphilic material, such as a polyethoxylated castor oil or derivative thereof, a polyoxyethylene alkyl ether, a polyoxyethylene sorbitan fatty acid ester, a polyoxyethylene stearate, a block copolymer of polyethylene oxide-polypropylene oxide-polyethylene oxide, a block copolymer of polypropylene oxide-polyethylene oxide-polypropylene oxide, a tetra-functional block copolymer of polyethylene oxide-polypropylene oxide, or a tetra-functional block copolymer of polypropylene oxide-polyethylene oxide. A dosage kit that includes the injectable, nonaqueous suspension and a method of administering the injectable, nonaqueous suspension are also disclosed. | 04-26-2012 |
20120107323 | KINASE PROTEIN BINDING INHIBITORS - The invention provides compounds capable of treating a subject suffering from or being susceptible to a cell proliferative disorder (especially, cancer), methods of identifying and using the compounds, pharmaceutical compositions and kits thereof. | 05-03-2012 |
20120128683 | AUTISM TREATMENT - A safe and effective treatment to curtail and cure autism spectrum disorders has been described in this invention using insulin, IGF-1, with multiple known adjuvant therapeutic agents, as well as other pharmaceutical, biochemical, nurticeuticals, and biological agents or compounds delivered through the olfactory mucosal region of the nose and external auditory meatus. | 05-24-2012 |
20120141491 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCERS AND PATHOGENIC INFECTIONS - The subject application provides small compounds that are able to increase/enhance autophagy in various cells. These compounds are useful in augmenting existing treatments of various cancers, microbial/viral infections, and neurodegenerative diseases. Thus, the subject application also provides methods of treating various types of cancers, microbial/viral infections, and neurodegenerative diseases. | 06-07-2012 |
20120148595 | GABA-LINKED ANTHRACYCLINE-LIPID CONJUGATES - The present invention relates to GABA-linked anthracycline-lipid conjugates and to methods of using the conjugates to treat cancer. Methods for making the GABA-linked anthracycline lipid conjugates are also provided. | 06-14-2012 |
20120148596 | MOLECULAR CONJUGATES COMPRISING HUMAN MONOCLONAL ANTIBODIES TO DENDRITIC CELLS - Isolated human monoclonal antibodies and antigen-binding portions thereof which specifically bind to dendritic cells are disclosed. Also disclosed are bispecifics, immunotoxins and antigen conjugates which include the antibodies or antibody portions. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies. | 06-14-2012 |
20120156212 | METHODS AND COMPOSITIONS FOR TREATING NEOPLASIA - The present invention relates to compounds as novel thymidylate synthase inhibitors, novel strategies to treat or prevent neoplasia in a subject, methods and compositions thereof. | 06-21-2012 |
20120171216 | PALMITATED MONOCLONAL ANTIBODY - The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of β-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD). | 07-05-2012 |
20120207762 | STABLE PHARMACEUTICAL FORMULATIONS - Stable pharmaceutical formulations and methods of making same are provided. In a general embodiment, the present disclosure provides a method of making a stable pharmaceutical formulation comprising adding one or more vitrifying additives to an aqueous pharmaceutical solution to raise the glass transition temperature of the aqueous pharmaceutical solution. The aqueous pharmaceutical solution can be cooled to a temperature of about −50° C. to about −10° C. The vitrifying additive enhances the formation of a glass or amorphous solid of the aqueous pharmaceutical solution at cryogenic temperatures (−50 to −10° C.), and the pharmaceutical formulation can be thawed to liquid form and administered to a mammalian subject. | 08-16-2012 |
20120213791 | 3,4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASE AND GLYCOGEN SYNTHASE KINASE-3 MODULATORS - The invention provides compounds of the formula (0) or salts or tautomers or N-oxides or solvates thereof, and combinations thereof with other anti-cancer agents, for use in the prophylaxis or treatment of disease states and conditions such as cancers mediated by cyclin-dependent kinase and glycogen synthase kinase-3. | 08-23-2012 |
20120219553 | USE OF A CD258 BINDING PHARMACEUTICAL SUBSTRANCE FOR MAKING A PHARMACEUTICAL COMPOSITION WITH DOSE-DEPENDENT EFFECT - The invention relates to the use of a CD28-specific superagonistic monoclonal antibody (MAB) or of a mimetic compound of the same, for producing a pharmaceutical composition, wherein the dosage is below or above a defined dosage limit. | 08-30-2012 |
20120231009 | Formulations of Antibody - A stable pharmaceutically formulation containing antibody, a buffer, a non-ionic surfactant, and a lyoprotectants/cryoprotectants. Also disclosed are associated methods for preparing, storing, and using such formulations. | 09-13-2012 |
20120237522 | ANTICANCER AGENT COMPRISING ANTI-PD-1 ANTIBODY OR ANTI-PD-L1 ANTIBODY - Provided is an anticancer agent which comprises an anti-PD-1 antibody or an anti-PD-L1 antibody as an active ingredient, functioning to reverse the unresponsiveness of iNKT cells in which anergy has been induced by administration with an iNKT cell ligand. The anti-PD-1 or anti-PD-L1 antibody blocks the PD-1/PD-L1-mediated signaling pathway not only to prevent the iNKT cell ligand-induced iNKT cell anergy, but also to reverse the unresponsiveness of already anergic iNKT cells to produce cytokines. In addition, the anti-PD1 or anti-PD-L1 antibody ensures the potent anti-tumor activity of iNKT cells as demonstrated by a significant reduction in the number of metastatic nodules in B16F10 melanoma metastasis models in vivo. Collectively, the anticancer agent can be very useful in the treatment of cancer, particularly metastatic cancer. | 09-20-2012 |
20120244165 | METHODS OF TREATING AMYLOIDOSIS COMPRISING THE USE OF ANTI-AMYLOID BETA ANTIBODIES - The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. | 09-27-2012 |
20120251545 | Therapeutic Combinations Of Hydroxybenzamide Derivatives As Inhibitors Of HSP90 - The invention provides a combination comprising an Hsp90 inhibitor compound of the formula (VII): | 10-04-2012 |
20120263730 | RECEPTORS OF RSPO2 AND RSPO3 - The present invention relates to the finding that Syndecans (Sdc) are receptors of Rspondin-2 (Rspo2) and Rspondin-3 (Rspo3). Thus, the present invention relates to the identification of Rspo2, Rspo3 and/or Sdc activity modulators by determining if a test compound has the ability to modulate the binding of an Rspo2 and/or Rspo3 polypeptide to an Sdc polypeptide. Further, the invention refers to novel uses for antagonists of Rspo2 and/or Rspo3 in the treatment of Sdc-associated disorders and for Sdc antagonists in the treatment of Rspo2- and/or Rspo3-associated disorders. | 10-18-2012 |
20120276108 | MONOSACCHARIDE-BASED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE AND INFLAMMATORY DERMATOLOGICAL DISEASES - The present invention relates to compounds and methods which may be useful as inhibitors of glycolysis, inhibitors of protein glycosylation, anti-virals, and down-regulators of insulin receptor and IGF-1 receptor for the treatment or prevention of inflammatory dermatological diseases or proliferative dermatological diseases. | 11-01-2012 |
20120276109 | TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE IMMUNE RESPONSES TO THERAPEUTIC PROTEINS - Disclosed are synthetic nanocarrier compositions, and related methods, comprising therapeutic protein APC presentable antigens and immunosuppressants that provide tolerogenic immune responses specific to therapeutic proteins. | 11-01-2012 |
20120282261 | Deuterated analogs of (4S)-4-Ethyl-4-hydroxy-11-[2- (trimethylsilyl)ethyl]-1H-pyrano[3', 4':6,7] indolizino [1,2-b]quinoline-3,14(4H, 12H)-dione and methods of use thereof - The present invention discloses: (i) two novel deuterated Karenitecin® analogs, pharmaceutically-acceptable salts, and/or derivatives thereof; (ii) methods of synthesis of said novel deuterated Karenitecin® analogs, pharmaceutically-acceptable salts, and/or derivatives thereof; (iii) pharmaceutically-acceptable formulations comprising said novel deuterated Karenitecin® analogs, pharmaceutically-acceptable salts, derivatives thereof; and/or, optionally, one or more additional chemotherapeutic agents; and (iv) methods of administration of said novel deuterated Karenitecin® analogs, pharmaceutically-acceptable salts, derivatives thereof; and/or, optionally, one or more additional chemotherapeutic agents, to subjects in need thereof. | 11-08-2012 |
20120294866 | PHARMACEUTICAL FORMULATION FOR PROTEINS - The present invention provides a liquid pharmaceutical formulation comprising a therapeutic protein, a surfactant and at least an antioxidant selected from the group of radical scavengers, chelating agents or chain terminators. | 11-22-2012 |
20130022609 | METHOD OF TREATING ANDROGEN INDEPENDENT PROSTATE CANCER - The present invention is directed to a method treating prostate cancer. The method comprises administering to a patient in need thereof at least one compound selected from N-methyl-Δ3,3′-dihydroindole-2,2′ diketone; N-1-(β-D-O-triacetyl-xylopranosyl)-Δ3,3′-dihydroindole-2,2′ diketone; and N-1-(β-D-O-triacetyl-xylopranosyl)-N′-methyl-Δ3,3′-dihydroindole-2,2′ diketone. Preferably the compound is in an amount sufficient to inhibit growth, invasion, and/or metastasis of prostate cancer cells. | 01-24-2013 |
20130034562 | SELECTIVE ANDROGEN RECEPTOR MODULATORS FOR TREATING DIABETES - This invention provides use of a SARM compound or a composition comprising the same in treating and preventing muscle wasting in patients with non-small cell lung cancer (NSCLC); treating pre-cachexia or early cachexia (preventing muscle wasting in a cancer patient); treating and preventing loss of physical function due to cancer or cancer therapy; increase of physical function; and increasing survival in a patient with NSCLC, wherein the patients are subjected to cancer therapy. | 02-07-2013 |
20130039920 | SPECIFIC BINDING PROTEINS AND USES THEREOF - The invention provides specific binding proteins and the uses thereof. Particularly, the present invention provides a monoclonal antibody which can effectively bind to epidermal growth factor receptor variant type III (EGFRvIII) or can partially bind to the epidermal growth factor receptor (EGFR) over-expressed in cells, but not bind to EGFR normally-expressed in cells. Furthermore, the present invention said antibody has obvious therapeutic effect on a tumor cell line expressing the EGFRvIII. The invention also provides a method for preparing said monoclonal antibody and a pharmaceutical composition comprising said monoclonal antibody. | 02-14-2013 |
20130115219 | Expression Vector - The present invention provides an expression vector for cell-surface expression of proteins. | 05-09-2013 |
20130122010 | Diagnostic Methods Based on Somatically Acquired Rearrangement - A monitoring method comprising identifying a somatically acquired genomic rearrangement associated with a disease state in a patient by genome-wide analysis of the nucleic acid of that patient and monitoring the changes in levels of nucleic acid containing the genomic rearrangement, and/or quantifying the levels of nucleic acid containing the genomic rearrangement as a marker for the progression or severity of a disease in that patient is described. Use of a monitoring process of the invention in assessment of efficacy of a therapy and use of a patient specific genomic rearrangement as a biomarker for disease progression in that patient are also described. | 05-16-2013 |
20130164299 | LLT-1 ANTIBODIES WITH NEW FUNCTIONAL PROPERTIES - The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (LLT1), to polynucleotides encoding such antibodies and to cells that express such antibodies. Antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which LLT1- and CD161-expressing cells play a role in disease pathogenesis. | 06-27-2013 |
20130209476 | TREATMENT OF INFLAMMATORY DISORDERS - A method is provided for treating certain inflammatory disorders by inhibiting cadherin-11 function using a cadherin-11 antagonist. | 08-15-2013 |
20130209477 | AGENTS AND METHOD FOR TREATING INFLAMMATION-RELATED CONDITIONS AND DISEASES - Gene-modified, inflammation-specific monocytes that comprise a 1-alpha-hydroxylase gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme when the monocytes transdifferentiate into gene-modified, inflammation-specific macrophages. Gene-modified, inflammation-specific macrophages that comprise a 1-alpha-hydroxylase gene. A method for treating one or more than one inflammation-related condition or disease, the method comprising administering gene-modified, inflammation-specific monocytes that comprise a 1-alpha-hydroxylase gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme when the monocytes transdifferentiate into gene-modified, inflammation-specific macrophages. | 08-15-2013 |
20130224213 | Compositions and Methods for Stabilizing Protein-Containing Formulations - The present invention relates to use of certain alkylglycoside compositions for the prevention of aggregation and oxidation of antibodies and other proteins in therapeutically useful formulations thereof. | 08-29-2013 |
20130259870 | Galactomannan polysaccharide composition for the treatment of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease - Aspects of the invention provides provide methods for treatment of NASH and associated liver fibrosis. In particular, aspects of the invention relate to the therapeutic formulation comprising a galactomannan polysaccharide compound for the treatment of NASH and associated liver fibrosis. | 10-03-2013 |
20130287787 | MONOCLONAL ANTIBODIES THAT REACT WITH THE CAPSULE OF BACILLUS ANTHRACIS - The present disclosure relates to monoclonal antibodies that bind poly-γ-D-glutamic acid (γDPGA), which is present on the surface of | 10-31-2013 |
20130302342 | HUMAN LACTOFERRIN DERIVED PEPTIDE FOR USE AS AN ANTIGEN MASKING AGENT - The invention refers to a human lactoferrin derived peptide for use as an antigen masking agent in the production of a pharmaceutical composition for delivery of a biological active substance in a mammalian organism, where the biological active substance is able to induce an undesired immune response by the mammalian organism, where the pharmaceutical composition comprises a supramolecular aggregate of the biological active substance and the human lactoferrin derived peptide, with the effect that after delivery of pharmaceutical composition to the mammalian organism, there is no or only a diminished induction of the undesired immune response against the biological active substance. | 11-14-2013 |
20140050737 | COMPOUNDS FOR ENZYME INHIBITION - Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles. | 02-20-2014 |
20140065157 | AGENTS AND METHOD FOR TREATING INFLAMMATION-RELATED CONDITIONS AND DISEASES - Gene-modified, inflammation-specific monocytes that comprise a 1-alpha-hydroxylase gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme when the monocytes transdifferentiate into gene-modified, inflammation-specific macrophages. Gene-modified, inflammation-specific macrophages that comprise a 1-alpha-hydroxylase gene. A method for treating one or more than one inflammation-related condition or disease, the method comprising administering gene-modified, inflammation-specific monocytes that comprise a 1-alpha-hydroxylase gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme when the monocytes transdifferentiate into gene-modified, inflammation-specific macrophages. | 03-06-2014 |
20140072571 | OSTEOPOROSIS ASSOCIATED MARKERS AND METHODS OF USE - Disclosed are methods of identifying subjects with osteoporosis or osteopenia, subjects at risk for developing osteoporosis, osteopenia, and bone fractures, methods of evaluating the effectiveness of osteoporosis treatments in subjects with osteoporosis or osteopenia, and methods of selecting therapies for treating osteoporosis or osteopenia, using biomarkers. | 03-13-2014 |
20140099319 | Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders - Methods and compositions of the invention relate to the treatment of diabetic nephropathy and associated disorders. In particular, the methods and compositions use a pharmaceutical-grade galactose-pronged carbohydrate or pharmaceutical compositions thereof alone or in combination with other therapeutic agents. | 04-10-2014 |
20140141005 | AGENTS AND METHOD FOR TREATING INFLAMMATION-RELATED CONDITIONS AND DISEASES - Gene-modified, inflammation-specific monocytes that comprise a 1-alpha-hydroxylase gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme when the monocytes transdifferentiate into gene-modified, inflammation-specific macrophages. Gene-modified, inflammation-specific macrophages that comprise a 1-alpha-hydroxylase gene. A method for treating one or more than one inflammation-related condition or disease, the method comprising administering gene-modified, inflammation-specific monocytes that comprise a 1-alpha-hydroxylase gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme when the monocytes transdifferentiate into gene-modified, inflammation-specific macrophages. | 05-22-2014 |
20140186360 | PHOSPHORYLCHOLINE CONJUGATES AND CORRESPONDING ANTIBODIES - In subjects with hypertension, increases in intima-media thickness (IMT) at four years were less in subjects also having high autoantibodies particularly IgM, to phosphorylcholine. The presence or absence of autoantibodies, particularly IgM, against phosphrylcholine is thus related to an increased or decreased risk of developing ischemic cardiovascular diseases. A method to determining antibodies, particularly IgM antibodies, toward phosphorylcholine is proposed in this invention to identify subjects at risk of developing ischemic cardiovascular diseases. Animal experiments show that medium to high levels of antibodies, particularly IgM antibodies, can be detected in plasma after active immunization with a keyhole limpet hemocyanin (KLH)-phosphorylcholine conjugate. Pharmaceutical compositions comprising a phosphorylcholine conjugate or antibody preparations, for example a monoclonal antibody, with specificity to a phosphorylcholine conjugate is proposed as is use of these compositions as active or passive immunogens in the treatment or prevention of atherosclerosis. | 07-03-2014 |
20140199319 | METHODS FOR INCREASING THE EFFICIENCY OF HYBRIDOMA GENERATION - Disclosed herein are methods for improving the efficiency of the production of hybridomas, e.g., through enrichment of IgG expressing B cells. Also disclosed are hybridoma compositions produced using these methods as well as methods for producing antibodies with the hybridomas. | 07-17-2014 |
20140234327 | MONOCLONAL ANTIBODY AGAINST HUMAN NON-SMALL CELL LUNG CARCINOMA AND USE THEREOF - The invention discloses a monoclonal antibody against human non-small cell lung carcinoma and a use of the monoclonal antibody. The monoclonal antibody is secreted by a hybridoma cell strain which is deposited as CCTCC Access Number No.: C201172. It has high yield and high titer, and has specific reactivity against lung adenocarcinoma and squamous carcinoma cell lines. Therefore, the monoclonal antibody may be applied in preparing drugs for treating human non-small cell lung carcinoma. | 08-21-2014 |
20140248274 | STABLE LYOPHILIZED PHARMACEUTICAL PREPARATIONS OF MONOCLONAL OR POLYCLONAL ANTIBODIES - The invention concerns lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies which contain a sugar or an amino sugar, an amino acid and a surfactant as stabilizers. In addition the invention concerns a process for the production of this stable lyophilisate as well as the use of a sugar or amino sugar, an amino acid and a surfactant as stabilizers for therapeutic or diagnostic agents containing antibodies. | 09-04-2014 |
20140255418 | COMPOSITE BIOMARKERS FOR NON-INVASIVE SCREENING, DIAGNOSIS AND PROGNOSIS OF COLORECTAL CANCER - The present invention concerns particular biomarkers for diagnosing and/or prognosticating colorectal cancer, in particular in a non-invasive manner. The methods and compositions concern analysis of methylation patterns of one or more genes from a set of 29 genes identified as described herein. In certain embodiments, the gene set includes at least P15.INK4b, SST, GAS7, CNRIP1, and PIK3CG. | 09-11-2014 |
20140294851 | CLEAVABLE DRUG CONJUGATES, COMPOSITIONS THEREOF AND METHODS OF USE - Base-labile crosslinkers, base-labile conjugates comprising such crosslinkers, methods of their synthesis and use are disclosed. | 10-02-2014 |
20140302051 | Biocompatible Hydrogel Polymer Formulations for the Controlled Delivery of Biomolecules - Provided herein are biocompatible hydrogel polymers capable of gelling in vivo comprising a therapeutic agent such as a protein or other biomolecule and kits comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and at least one therapeutic agent. The biocompatible hydrogel polymer is bioabsorbable and releases the therapeutic agent at a target site, avoiding systemic exposure and achieving a controlled delivery. | 10-09-2014 |
20140308292 | FAMILY OF PAIN PRODUCING SUBSTANCES AND METHODS TO PRODUCE NOVEL ANALGESIC DRUGS - A method may include treating pain, shock, and/or inflammatory conditions in a subject. A method may include using a therapeutically effective amount of an antibody, a lipoxygenase inhibitor, a cytochrome P-450 enzyme inhibitor, and/or an antioxidant configurable to at least partially treat pain, shock, and/or inflammatory conditions in a subject. A method of treating pain, shock, and/or inflammatory conditions in a subject may include inactivating or preventing at least one linoleic acid metabolite to treat certain conditions (e.g., pain, shock, and/or inflammation). | 10-16-2014 |
20140314778 | FORMULATIONS WITH REDUCED OXIDATION - The invention provides formulations comprising a protein in combination with a compound that prevents oxidation of the protein. The invention also provides methods for making such formulations and methods of using such formulations. The invention further provides methods of screening for compounds that prevent oxidation of a protein in a protein composition and methods of preventing oxidation of a protein in a formulation. | 10-23-2014 |
20140314779 | CELL CULTURE COMPOSITIONS WITH ANTIOXIDANTS AND METHODS FOR POLYPEPTIDE PRODUCTION - Cell culture media comprising antioxidants are provided herein as are methods of using the media for cell culturing and polypeptide production from cells. Compositions comprising polypeptides, such as therapeutic polypeptides, produced by the methods herein are also provided. | 10-23-2014 |
20140335098 | METHOD OF ISOLATING HUMAN ANTIBODIES - Provided is a novel method of isolating and producing human antibodies with desired specificity from human B cells. In particular, a method of isolating human antibodies from memory B cells obtained from patients which suffer from a disease which is caused by or involves activation of the immune system, for example autoimmune and inflammatory disorders is described. | 11-13-2014 |
20140341920 | VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER - The present disclosure relates to compositions and therapeutic methods for activating an immune response in a patient in need thereof. In a preferred embodiment, the subject methods and compositions are able to antagonize the activity of VISTA, a naturally occurring “checkpoint” protein which contributes to immune tolerance, optionally in combination with an antagonist of a second checkpoint pathway such as PD-1. For example, such methods and compositions may be suitable for preventing and treating colon cancer or another cancer. An exemplary VISTA antagonist, specifically, an anti-VISTA antibody, is demonstrated herein to activate an immune response against cancer cells in vitro and in vivo, thereby conferring protective anti-tumor immunity which decreased tumor burden. Additionally, an additive benefit was observed when a VISTA antagonist was used in combination with a second checkpoint protein antagonist, specifically, an antibody against PD-1 ligand (PD-L1). | 11-20-2014 |
20140341921 | HUMAN-DERIVED BACTERIA THAT INDUCE PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLS - Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases. | 11-20-2014 |
20140348845 | ION EXCHANGE MEMBRANE CHROMATOGRAPHY - Methods of enhancing efficiency of downstream chromatography steps for purification of proteins comprising: (a) passing a composition comprising a polypeptide of interest and various contaminants through an ion exchange membrane, wherein the polypeptide and the membrane have opposite charge, at operating conditions comprised of a buffer having a pH sufficiently distinct from the pi of the polypeptide to enhance the charge of the polypeptide and a low ionic strength effective to prevent the shielding of charges by buffer ions, which cause the membrane to bind the polypeptide and at least one contaminant, (b) overloading the ion exchange membrane such that at least one contaminant remains bound to the membrane while the polypeptide of interest is primarily in the effluent; (c) collecting the effluent from the ion exchange membrane comprising the polypeptide of interest; (d) subjecting the membrane effluent comprising the polypeptide of interest to a purification step of similar charge as the previous membrane, and (e) recovering the purified polypeptide from the effluent of the charged ion exchange chromatography purification step. | 11-27-2014 |
20150017174 | Composition - The present invention relates to a composition for use in the treatment of an intestinal tract disorder caused by a gluten-associated protein, said composition comprising at least one agent which binds to the gluten-associated protein, characterized in that the composition is administered at the same time as or at most within 60 minutes after administration of at least one tannin to a patient. | 01-15-2015 |
20150125461 | BETA-GLUCAN IMMUNOTHERAPEUTIC METHODS - This disclosure describes, in one aspect, a method for identifying β-glucan binding to immune cells of a subject. Generally, the method includes obtaining a blood sample from the subject, the blood sample comprising immune cells, adding soluble β-glucan to at least a portion of the blood sample and incubating the mixture under conditions allowing the soluble β-glucan to bind to the immune cells, and detecting soluble β-glucan bound to the immune cells. In another aspect, this disclosure describes a method that generally includes identifying the subject as a low binder of β-glucan, and co-administering to the subject a soluble β-glucan and an antibody preparation capable of converting the subject from a low binder to a high binder. | 05-07-2015 |
20150140004 | HYDROXYCHOLESTEROL IMMUNOASSAY - Provided is a derivative of 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative. Further provided is an antibody composition comprising antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Additionally, a method of making antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Also, a method of assaying for 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Additionally provided is a kit for detecting 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. A method of detecting an enzyme or enzymes utilized in phase II drug metabolism is also provided. Also, a method of detecting an enzyme that synthesizes 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Further provided is a method of evaluating progression of multiple sclerosis in a patient. Also provided is a method of determining whether a treatment for multiple sclerosis in a patient is effective. Further, a method of evaluating progression of Huntington's disease in a patient is provided. Additionally provided is a method of determining whether a treatment for Huntington's disease in a patient is effective. | 05-21-2015 |
20150315247 | High-affinity peptide-based anticancer vaccination to overcome tumor resistance to immunostimulatory antibodies and to identify TCRs that can be used successfully in adoptive T cell therapy - The invention provides a methodology to use cancer vaccination to overcome tumor resistance to immunostimulatory antibodies. Our cancer vaccination approach relies on targeting mutant tumor-specific peptides that have high affinity for the major histocompatibility complex. Treatment with bacteria expressing high affinity tumor-specific peptides combined with anti-PD-L1 monoclonal antibody can eradicate long-established tumors resistant to anti-PD-L1 and anti-CTLA-4 alone. In addition, we discovered that adoptive transfer of T cells with this same vaccine-generated T cell receptor specificity can also eradicate long-established tumors. These results demonstrate that cancer vaccination approaches should target peptides with high peptide-MHC affinity to (i) overcome tumor resistance to immunostimulatory antibodies and (ii) identify T cell receptors that can be used successfully for adoptive T cell transfer. | 11-05-2015 |
20150337030 | METHODS TO TREAT ALZHEIMER'S DISEASE USING APOE INHIBITORS - Non-familial late-onset Alzheimer's disease (LOAD), a condition associated with the accumulation of the amyloid precursor protein-derived (APP) Abeta fragment in the brain, can be the consequence of combined genetic and environmental risk factors. One of these risk factors is the presence of the apolipoprotein E4 (APOE4) allele. This invention provides for a neuron model that can be used to screen and identify compounds that can prevent the APOE4-induced pre-LOAD state. This invention provides for methods for the treatment and/or prevention of a neurodegenerative disorder by using an inhibitor of APOE4, such as an antibody inhibitor, or by using an excess of APOE3 protein. | 11-26-2015 |
20150352101 | USE OF LEVOCETIRIZINE AND MONTELUKAST IN THE TREATMENT OF VASCULITIS - The embodiments described herein include methods and formulations for treating vasculitis. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient. | 12-10-2015 |
20160002593 | CELL CULTURE COMPOSITIONS WITH ANTIOXIDANTS AND METHODS FOR POLYPEPTIDE PRODUCTION - Cell culture media comprising antioxidants are provided herein as are methods of using the media for cell culturing and polypeptide production from cells. Compositions comprising polypeptides, such as therapeutic polypeptides, produced by the methods herein are also provided. | 01-07-2016 |
20160023983 | SUBSTITUTED AROMATIC COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, LIVER FIBROSIS,SKIN FIBROSIS AND CARDIAC FIBROSIS - The present invention relates to substituted aromatic compounds for use in prevention or treatment of various fibrotic diseases and conditions in subjects, including pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis, where the compound has the following formula: or a pharmaceutically acceptable salt thereof, wherein A is C | 01-28-2016 |
20160038519 | ADMINISTRATION OF KARENITECIN FOR THE TREATMENT OF ADVANCED OVARIAN CANCER, INCLUDING CHEMOTHERAPY-RESISTANT AND/OR THE MUCINOUS ADENOCARCINOMA SUB-TYPES - The present invention discloses and claims methods and compositions for the treatment of platinum and/or taxane cancer treating agent-resistant/-refractory sub-populations and/or the mucinous adenocarcinoma sub-type of ovarian cancer subjects with the silicon-containing highly lipophilic camptothecin derivative (HLCD), Karenitecin (also known as BNP1350; cositecan; 7-[(2′-trimethylsilyl)ethyl]-20(S) camptothecin). The administration of Karenitecin by intravenous (i.v.) and/or oral methodologies are also disclosed and claimed. Karenitecin analogues, including but not limited to, Germanium-substituted Karenitecin, Deuterated Karenitecin, and “flipped” E-ring Karenitecin, are disclosed and claimed. In addition, Karenitecin and one or more cancer treating agents administered either concomitantly or in series via oral and/or i.v. means, are also disclosed and claimed. Methods for the administration of Karenitecin to: (i) increase Progression Free Survival (PFS); (ii) increase the platinum-free time interval; (iii) decrease CA-125 marker levels; and (iv) mitigate or prevent chemotherapeutic drug-resistance from developing are disclosed and claimed herein. Methods for the use of Karenitecin to treat advanced solid tumors; refractory or recurrent solid tumors; recurrent malignant glioma; primary malignant glioma; persistent or recurrent epithelial ovarian or primary peritoneal carcinoma; and other identified cancer types are also disclosed and claimed. | 02-11-2016 |
20160137750 | METHOD OF TREATING A PATHOLOGICAL SYNDROME - A method of treating disorder or condition that relates to intracellular signal transmission of a neurotransmitter, comprising administration of an homeopathically potentized form of antibodies to an antigen, which antigen is a molecule capable of effecting the intracellular signal transmission of a neuroreceptor, in particular dopamine or serotonin. | 05-19-2016 |
20160250187 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | 09-01-2016 |
20180024131 | PCSK9 ANTIBODY, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 01-25-2018 |
20190144817 | CELL CULTURE COMPOSITIONS WITH ANTIOXIDANTS AND METHODS FOR POLYPEPTIDE PRODUCTION | 05-16-2019 |